A comparison of the wound healing dynamics in an acute and newly developed chronic wound model using Neutral endopeptidase, an inhibitor of Substance P. by Boodhoo, Kiara
1 
A comparison of the wound healing dynamics in an acute and 
newly developed chronic wound model using Neutral 
endopeptidase, an inhibitor of Substance P. 
By 
Kiara Boodhoo 
Thesis presented in the fulfilment of the requirements for the degree of Master of Science 
(Physiological Sciences) in the Faculty of Science at Stellenbosch University 
Supervisor: Dr Mari van de Vyver 




By submitting this thesis electronically, I declare that the entirety of the work contained 
therein is my own, original work, that I am the sole author thereof (save to the extent explicitly 
otherwise stated), that reproduction and publication thereof by Stellenbosch University will 
not infringe any third party rights and that I have not previously in its entirety or in part 
submitted it for obtaining any qualification. 





Chronic wounds affect millions of people with diabetes world-wide. Various diabetic wound 
healing animal models exist, none of which currently replicate chronic wounds in diabetic 
patients. Animal models that do not closely resemble human conditions delay application of 
promising therapeutic strategies in clinical settings. Substance P is a neuropeptide that 
promotes wound healing by binding to neurokinin-1 receptor initiating the inflammatory 
process. Neutral endopeptidase (NEP) is a zinc metalloprotease that degrades substance 
P, thereby hindering the healing process. Increased NEP enzymatic activity is evident in 
chronic wounds of diabetic patients unlike in current animal models. This study aimed to 
determine the optimum dose of NEP for injection into wound edges in obese pre-diabetic 
mice (B6.Cg- Lepob/J, ob/ob) in order to create a chronic non-healing wound. Thereafter, 
the study investigated wound healing dynamics of this chronic non-healing wound compared 
to an acute wound treated with saline. In addition to a saline control, three concentrations of 
NEP [low NEP (0.33 mg/µL), medium NEP (0.68 mg/µL) or high NEP (1.02 mg/µL)] were 
used to obtain a dose-response curve. NEP activities did not differ between treatment 
groups however, substance P was lower in the wound areas for high NEP compared to low 
NEP groups. Therefore, less substance P was present to initiate wound healing with high 
NEP.  MMP-9 was higher with high NEP treatment on day 2 compared to saline, low and 
medium NEP groups. Similarly, the cytokine profile within pooled samples of day 2 wound 
fluid was lowest with high NEP treatment. Therefore, high NEP application did mimic some 
characteristics of a chronic wound during the early stages post wounding, including delayed 
onset of inflammation. When comparing the healing dynamics of this chronic non-healing 
wound, induced by high NEP, to an acute wound [wild-type (C57BL/6J) saline-treated mice] 
that follows the normal progression of healing, the chronic wound displayed delayed wound 
closure (day 7), significantly greater MMP-9 expression (day 0, 2 and 7) with no formation 
of granulation tissue, re-epithelization and angiogenesis (day 7). Proteomic analysis of the 
acute saline-treated and chronic high NEP wounds at day 2 indicated significant differences 
in expression of proteins such as Stefin-1, Stefin-3, Microtubule-associated protein 1B, Band 
4.1-like protein 2, Caveolae-associated protein 1 and Gamma-synuclein. These proteins 
have not been previously described as involved in wound healing and may be directly 
involved or have downstream interactions in the wound healing processes. This study 
identified two proteins previously described as playing a role in wound healing, via their 
involvement in inflammation (Alpha-1- acid glycoprotein 1) and proliferation and remodelling 




diabetic mice resulted in a chronic wound model that better mimics human diabetic chronic 
wounds, which could be used to test various treatment strategies. High NEP administration 
resulted in less wound closure that could be explained by higher MMP-9, lower cytokine 







Chroniese wonde kom wêreldwyd onder miljoene mense met diabetes voor. Verskeie 
diermodelle vir diabetiese wondgenesing bestaan, maar geen repliseer tans chroniese 
wonde onder diabetiese pasiënte nie. Diermodelle wat nie voldoende met mensetoestande 
ooreenstem nie, belemmer die toepassing van belowende terapeutiese strategieë in kliniese 
omgewings. Substansie P is ŉ neuropeptied wat wondgenesing bevorder deur aan die 
neurokinien 1-reseptor te bind, wat die inflammatoriese proses in werking stel. Neutrale 
endopeptidase (NEP) is ŉ sinkmetalloprotease wat substansie P degradeer, waardeur die 
genesingsproses belemmer word. Verhoogde NEP ensimatiese aktiwiteit is sigbaar in 
chroniese wonde van diabetiese pasiënte, wat nie die geval in huidige diermodelle is nie. 
Die doel van hierdie studie was om die optimale dosis van NEP vir inspuiting in wondrande 
van vetsugtige prediabetiese muise (B6.Cg- Lepob/J, ob/ob) te bepaal ten einde ŉ chroniese 
niegenesende wond te skep. Daarna is die wondgenesingsdinamika van hierdie chroniese 
niegenesende wond met ŉ akute wond wat met ŉ soutoplossing behandel is, vergelyk. 
Benewens soutoplossingkontrole is drie konsentrasies van NEP (lae NEP [0.33 mg/µL], 
middelslag-NEP [0.68 mg/µL] of hoë NEP [1.02 mg/µL]) gebruik om ŉ dosisrepsonskromme 
te verkry. NEP-aktiwiteite het nie onder die behandelingsgroepe verskil nie, maar substansie 
P was wel laer in die wondareas vir die hoë NEP- vergeleke met die lae NEP-groepe. ŉ 
Kleiner hoeveelheid van substansie P was dus teenwoordig om wondgenesing met hoë NEP 
in werking te stel. Daar is spesifiek gevind dat MMP-9 hoër was in die hoë NEP- behandelde 
groep op dag 2, vergeleke met soutoplossing-, lae en middelslag-NEP-groepe. Eweneens 
was die sitokienprofiel in gemengde monsters van dag 2 se wondvloeistof die laagste met 
hoë NEP-behandeling. Hoë NEP-toepassing het dus wel enkele eienskappe van ŉ 
chroniese wond in die vroeë fases ná verwonding nageboots, insluitende vertraagde 
aanvang van inflammasie. Met vergelyking van die genesende dinamika van hierdie 
chroniese wond, deur hoë NEP geïnduseer, met ŉ akute wond (wilde tipe [C57BL/6J] 
soutoplossingbehandelde muise) het die chroniese wond vertraagde wondgenesing (dag 7) 
en aanmerklik groter MMP-9-uitdrukking (dag 0, 2 en 7) getoon, met geen vorming van 
granulasieweefsel, herepitelisasie en angiogenese in die wondarea van die chroniese wond 
nie (dag 7). Proteomiese analise van die akute soutoplossing- en chroniese hoë NEP-wonde 
op dag 2 het aanmerklike verskille in uitdrukking van proteïene (Stefin-1, Stefin-3, 
mikrotubulus-geassosieerde proteïen 1B, band 4.1-agtige proteïen 2, kaveola-
geassosieerde proteïen 1 en gamma-sinukleïen) getoon, wat nog nie voorheen met 




maar het moontlike stroomaf-interaksies in die wondgenesingsproses. Hierdie studie het 
slegs twee proteïene geïdentifiseer wat volgens die literatuur ŉ rol in wondgenesing speel 
deur hul betrokkenheid by inflammasie (alfa-1-suur glikoproteïen 1) en proliferasie en 
hermodellering (Nidogen-1). Die gevolgtrekking is dat hoë NEP-toediening in die wondrande 
van vetsugtige prediabetiese muise ŉ wond geskep het wat ŉ chroniese wond beter naboots 
as laer NEP-konsentrasies of soutoplossingtoediening. Hoë NEP-toediening het tot minder 
wondgenesing gelei, wat die gevolg mag wees van hoër MMP-9, laer sitokien-inhoud in 
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Chapter 1 : Introduction 
Wound healing plays a vital role in maintaining the integrity of tissue following injury or during 
disease (Shaw and Martin, 2009). It consists of four major phases namely haemostasis 
(phase 1), inflammation (phase 2), proliferation (phase 3) and remodelling (phase 4)  (Eming 
et al., 2007) (refer to chapter 2, section 2.1). These stages do not always occur distinctively 
but involves the coordination and activation of various cell types and signalling pathways to 
maintain the integrity of the tissue (Gurtner et al., 2008). This ensures the rapid repair of the 
wound whilst utilizing the least amount of energy. The wound healing process is however 
hindered in diseases such as Type 2 Diabetes Mellitus (T2DM) due to its deviant pathology. 
The pathogenesis of uncontrolled T2DM involves persistent hyperglycaemia (elevated blood 
glucose levels) resulting in the accumulation of advanced glycation end-products (AGEs) 
(glycosylated proteins and lipids) (Singh et al., 2014, Vlassara and Uribarri, 2014). 
Consequently, oxidative stress is increased and a chronic low grade self-perpetuating pro-
inflammatory state develops (Goh and Cooper, 2008, Zhong et al., 2017, Lasselin and 
Capuron, 2014, Pradhan et al., 2009). Together, this toxic microenvironment leads to tissue 
damage and cellular dysfunction and is the underlying cause for co-morbidities such as 
retinopathy and non-healing wounds (also known as diabetic foot ulcers) (Zhao et al., 2016).   
Given the complex nature of non-healing diabetic wounds, there are currently no effective 
treatment strategies, making it a global economic burden. In 2017, approximately 8.8% of 
the world’s population was affected by diabetes and this percentage is projected to increase 
to 9.9% by the year 2045 (Cho et al., 2018). The prevalence of diabetic foot ulcers in diabetic 
patients is approximately 6.6% (Zhang et al., 2016). A different study found that due to the 
lack of effective treatment options the recurrence rate of diabetic wounds is 22.1% (Fu et 
al., 2019). This problem is further exacerbated and perpetuated by the lack of appropriate 
animal models to test novel therapeutic strategies. There is thus the need for an animal 
model that replicates the microenvironment within diabetic wounds as observed in the 
clinical setting. A better understanding of the complex nature of these wounds will 
furthermore aid in the development of more effective treatments. 
In diabetic patients, pathogenesis-induced neuropathy is one of the leading causes for the 
development of non-healing wounds (Pradhan et al., 2009). It is characterized by the 
insufficient production of neuropeptides such as substance P and the over production of 
Neutral endopeptidase (NEP), an enzyme that degrades substance P (Olerud et al., 1999, 
Antezana et al., 2002). Substance P is secreted by sensory nerves and inflammatory cells 




neurokinin-1 receptor (NKR-1), and has been shown to promote the wound healing process 
in both diabetic and non-diabetic skin wounds by initiating the second phase of healing, 
namely inflammation (Leal et al., 2015). Overproduction of the cell surface enzyme NEP, 
that degrades substance P, therefore hinders the onset of the healing process (Olerud et 
al., 1999).  
In a patient-based study, Antezana et al. (2002) observed an increase in NEP enzymatic 
activity in the ulcer margins (wound edges) of diabetic patients (~ 14 fold) compared to non-
diabetic controls, suggesting its role in chronic diabetic wounds. The relevance of this study 
has been confirmed by various research groups over the following decade. In vitro models 
that mimic this effect have been developed by exposing normal endothelial cells to high 
glucose (Wang et al., 2009). Raised NEP levels are not characteristic of wounds in current 
diabetic animal models; this suggests that the animal models do not accurately reflect the in 
vivo human scenario, which could in turn negatively impact appropriate drug development. 
The main purpose of this research project was thus to utilize NEP enzyme activity to develop 
a mouse chronic wound model that more closely mimics diabetic foot ulcers in patients and 
















Chapter 2 : Literature Review 
2.1 Overview of the wound healing process 
Cutaneous wound healing is an essential process for maintaining tissue homeostasis and 
preserving its physiological function. It is a very complex and coordinated process that 
involves the activation and inactivation of the immune system, various intra- and extra-
cellular components, signalling pathways and paracrine factors (Gurtner et al., 2008). 
Healing occurs in four very specific phases (sections 2.1.1-2.1.4) and dysregulation thereof 
can cause wounds to become chronic with debilitating consequences for patients. 
 
2.1.1 Phase 1: Haemostasis 
Haemostasis is the first stage to occur immediately after injury. It is characterized by 3 
components i.e. vasoconstriction, platelet plug formation and coagulation. The 
vasoconstriction stage involves the contraction of smooth muscles in the  blood vessel walls 
to prevent excessive blood loss (Young and McNaught, 2011). This stage is followed by 
platelet plug formation which is mediated by the interaction of platelets, the vessel walls and 
adhesion proteins (such as integrins, glycoproteins and cadherins) (Xu et al., 2016). 
Platelets recognise the exposed fibrous matrix and the vascular endothelial cell lining in the 
injured area.  As a result, they become activated to trigger the secretion of clotting  factors 
such as thrombin and fibrin (Sira and Eyre, 2016). The downstream blood clotting cascade 
plays a crucial role in platelet plug formation (Periayah et al., 2017). The fibrin matrix within 
the platelet plug serves as a scaffold for infiltrating immune cells during the second phase 
of healing (Zilberman, 2011). In a review Young and McNaught (2011) discussed the role 
that platelets play in stimulating angiogenesis via the secretion of platelet derived growth 
factor (PDGF), transforming growth factor β (TGF-β) and fibroblast growth factor (FGF) in 
the subsequent proliferative stage of healing (phase 3). 
 
2.1.2 Phase 2: Inflammatory immune response  
Inflammation occurs in the first 72 hours (3-days) post injury and involves the infiltration of 
a variety of immune cells (neutrophils, monocytes/macrophages and lymphocytes) into the 
wounded area. Phagocytic neutrophils start infiltration immediately post injury and remain 
within the wounded area for the first 48 hours. They function to phagocytose and de-




and antimicrobial proteases (neutrophil elastase, cathepsin G and proteinase-3) whilst 
proteolytic enzymes [matrix metalloprotease (MMP)-2 and MMP-9] degrade non-viable 
collagen tissue (Zhao et al., 2016, Larouche et al., 2018, Stapels et al., 2015). Neutrophils 
subsequently undergo apoptosis or are removed from the injured area through macrophage-
mediated phagocytosis (Young and McNaught, 2011).  
Coinciding with neutrophil infiltration, monocytes and tissue resident macrophages with a 
pro-inflammatory phenotype (M1) fill the wounded area between 24-72 hours (day 1-3) post 
injury (see the wound area of Figure 2.1). The infiltrating monocytes differentiate into M1 
macrophages and together with tissue-resident monocytes that mature into macrophages, 
both contribute to phagocytosis, presentation of antigens (to trigger a T- lymphocyte immune 
response) and secrete a variety of chemokines and cytokines (see the dermal layer of 
Figure 2.1) (Fujiwara and Kobayashi, 2005). The release of tumour necrosis factor-α (TNF-
α), interleukin (IL)-1, IL-6, IL-8 and IL-12 by M1 macrophages improves vascular 
permeability and together with chemokines [thymus and activation-regulated chemokine 
(CCL17/TARC), macrophage-derived chemokine (CCL22/MDC) and CCL24/Eotaxin-2], 
increase the influx of inflammatory cells into the wounded area (Owen and Mohamadzadeh, 
2013).  
Once the wound is clear of debris and bacteria the macrophage population shifts its 
phenotype to have a predominantly anti-inflammatory (M2) function. This phenotype switch 
is a crucial step in wound healing, since it facilitates the transition from the destructive pro-
inflammatory phase (phase 2) to the growth promoting proliferative phase (phase 3) of 
healing. The M2 macrophages secrete anti-inflammatory cytokines (IL-10, IL-13 and IL-8) 
and chemokines [monocyte chemo-attractant protein-1 (MCP-1), macrophages 
inflammatory protein – 1 beta (MIP-1β/ CCL4) and Regulated on Activation, Normal T Cell 
Expressed and Secreted (RANTES)] to inhibit the inflammatory response and growth 
promoting factors [vascular endothelial growth factor (VEGF), TGF-β, epidermal growth 
factor (EGF), FGF and PDGF] to initiate regeneration by augmenting granulation tissue 





Figure 2.1. Haemostasis and inflammatory phases of wound healing. Haemostasis and inflammation are 
the first two phases of healing to occur and last for the first 72 hours post injury. In the haemostasis stage 
(phase 1) a platelet plug forms, vasocontraction and coagulation occurs to prevent blood loss. The 
inflammation stage (phase 2) is facilitated by the infiltration of various immune cells and functions to 
phagocytose cellular debris and foreign particles within the wound. Image adapted from Gurtner et al. (2008). 
 
2.1.3 Phase 3: Proliferation 
Proliferation, alternatively referred to as the proliferative phase of healing, occurs between 
2 and 10 days post injury and is characterized by several concurrent processes namely, 
angiogenesis, collagen deposition, granulation tissue formation and re-epithelisation (wound 
closure, refer to Fig. 2.2) (Li et al., 2007). This phase therefore involves the action of 
numerous cell types (keratinocytes, epithelial cells, fibroblasts, endothelial cells, 
stem/progenitor cells) and is mediated by the increased secretion of growth promoting 
factors such as VEGF, TGF-β and EGF.   
Upon stimulation by macrophage-derived growth factors and cytokines such as IL-1, TGF-
β, EDGF and PDGF,  tissue resident fibroblasts proliferate and migrate to the wound edges 
before differentiating into myofibroblasts (Kalluri and Zeisberg, 2006). Myofibroblasts 
express α-smooth muscle actin (α-SMA) that gives them the ability to physically contract 
and by doing so assist in decreasing the wound size. Following contraction, the wound area 
undergoes re-epithelialization for complete wound closure to occur (Bhowmick et al., 2004). 
Activated fibroblasts also secrete collagen, fibronectin and other matrix proteins that result 




(Gurtner et al., 2008). The interactions between the fibroblasts and myofibroblasts are 
essential in the secretion of collagen III to form new extracellular matrix (ECM) within the 
wounded area. At the same time, angiogenesis that is mediated by the action of endothelial 
progenitor cells restore the capillary network within the granulation tissue. Together, these 
cell interactions form the basis for keratinocytes to migrate and proliferate to re-establish the 
epithelium (Gonzalez et al., 2016).  
All the cells involved in the proliferative phase of the healing process are located within the 
granulation tissue at this point. These reparative cellular mediators must then either mature, 
migrate out of the wounded area or undergo apoptosis to allow for tissue remodelling to 
occur.  
Below is an illustration of the proliferative phase of healing process (Fig. 2.2). Take note the 
main proliferative cells are epithelial cells that migrate in order to close the wound site. 
 
 
Figure 2.2. Proliferative stage of wound healing. The proliferative stage of wound healing (phase 3) occurs 
between 2 to 10 days post wounding and involves angiogenesis, collagen deposition, granulation tissue 
formation and re-epithelisation. Image adapted from Gurtner et al. (2008). 
 
2.1.4 Phase 4: Tissue remodelling 
Tissue remodelling occurs after complete wound closure at about 2 weeks post injury and 
can continue for up to a year (Velnar et al., 2009). During this process, the collagen III within 
the ECM is degraded by MMPs and is replaced with collagen I that is secreted by fibroblasts 
(Zhao et al., 2016). This remodelling of the granulation tissue restores the functional capacity 





Figure 2.3. Remodelling stage of wound healing. Remodelling (phase 4) occurs between 2 weeks and a 
year post wounding. During this stage of healing collagen III is replaced with collagen I via MMP degradation 
to restore the structural and functional integrity of the tissue. Image adapted from Gurtner et al. (2008). 
 
Below is a detailed overview of the paracrine factors and their downstream signalling 
pathways involved in each of the phases of healing (Table 2.1). Studies have shown that in 
diabetic patients there is a disruption and dysregulation in the progression of inflammation 
to proliferation which can cause a wound to become chronic and subsequently inhibit the 4 
phases of healing, leading to chronic wounds. However, the study of this disruption in animal 




Table 2.1: Paracrine Factors involved in wound healing 
 Secreted by Phase in 
wound healing  
Function Signalling pathway 
Platelet derived 
growth factor (PDGF) 
Platelets Haemostasis • Stimulates proliferation of smooth muscle cells 
and fibroblasts. 
• Promotes angiogenesis (Diegelmann and 
Evans, 2004). 
• Collagenase production.  
• Functions via PDGF receptor 
(PDGFR) α and β.(Canalis, 
2008). 




• Promotes expression of IL-6, IL-8, MCP-1, 
COX-2 (Weber et al., 2010). 
• Functions via IL1 Receptor (IL-
1R). 




• Regulation of angiogenesis and deposition of 
collagen (Lin et al., 2003). 
• Proliferation of neutrophils, B cells and T cells. 
• Functions via IL6 Receptor (IL-
6R). 




• Migration and activation of neutrophils (Bickel, 
1993). 
• Functions via IL-8 Receptor α 
and  IL-8 Receptor β(Ben-
Baruch et al., 1995). 




• Inhibition of angiogenesis. 
• Promotes secretion of IF-γ.  
• Macrophage chemotaxis. 
• Up regulation of MMP 9 (Matias et al., 2011). 
• Functions via IL-12 Receptor 
(IL-12R). 







• Upregulates collagen I synthesis. 
• Anti-inflammatory macrophage polarization. 
• Promotes synthesis of fibrin (Larouche et al., 
2018). 
• Functions by activating  SP1, 
NF-κB, and STAT6 pathways 
to promote Collagen I 









• Stimulates synthesis of collagen and 
MMPs.(Mast and Schultz, 1996). 
• Promotes proliferation of fibroblasts.  
• Functions via TNF-R1p55, 
TNF-R2p75 receptors which in 
turn activates the (NF)-κB 
transcription and MAPK 
pathways (Cho et al., 2007). 
     




 Secreted by Phase in 
wound healing  
Function Signalling pathway 
Transforming growth 








• Macrophage attractant.  
• Stimulates macrophages to secrete FGF, 
PDGF, TNFα and IL-1. 
• Initiates fibroblasts and keratinocytes. 
chemotaxis.(Diegelmann and Evans, 2004). 
• Promotes migration of fibroblasts and 
keratinocytes. 
• Wound closure. 
• Stimulates TIMP. 
• Establishment of Collagen matrix (Young and 
McNaught, 2011). 
• Function via TβR I and TβR II 
which in turn activates Smad 
transcription signalling pathway 
(Finnson et al., 2013). 
Epidermal growth 





Proliferation • Formation of granulation tissue.  
• Proliferation and migration of epithelial cells, 
keratinocytes and fibroblasts. 
• Functions via Epidermal 
growth factor receptor (EGFR) 
(Bodnar, 2013). 
Vascular Endothelial 






Proliferation • Mediates angiogenesis. 
• Promotes proliferation and migration of 
endothelial cells (Li et al., 2007). 
• Collagen deposition. 
• Epithelialization (Bao et al., 2009). 
• Function via  Flt-1 (VEGFR-1) 
and KDR (VEGFR-2) 
receptors found on the blood 
vessels and surface of 
endothelial cells (Bao et al., 
2009). 
Fibroblast growth 




Proliferation • Stimulates angiogenesis. 
• Proliferation of fibroblasts. 
• Deposition of collagen matrix. 
• Wound contraction. 
• Function via Fibroblast growth 
factor receptors (FGFR) which 
in turn activates the STAT 
signalling pathway (Ornitz and 
Itoh, 2015).  
 
Footnotes:  The table indicates the origin, function and some of the potential downstream signalling pathways of the most prominent cytokines involved in wound 
healing. Abbr:  PDGF, Platelet derived growth factor; IL, Interleukin; COX-2: cyclooxygenase-2;  MCP-1, Monocyte chemoattractant protein-1; SP1, Specificity 
protein 1; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; TIMP, Tissue inhibitor of metallo-protease; MMP, Matrix metalloprotease; IFN-γ, 
Interferon gamma; STAT6, Signal transducer and activator of transcription 6; MAPK,  mitogen-activated protein kinase; TNF-α, Tumour necrosis factor-α; FGF, 





2.2  Overview of chronic wounds 
Chronic wounds are injuries that are unable to heal in a timely manner and often occur due 
to an underlying pathological condition. Depending on the underlying cause, chronic wounds 
are subdivided into three main classes i.e. leg ulcers (associated with venous disease), 
pressure ulcers (associated with prolonged bed rest) and diabetic foot ulcers (associated 
with uncontrolled hyperglycaemia). Of these, diabetic foot ulcers are the most common, very 
difficult to treat and often necessitate amputation (Alexiadou and Doupis, 2012, Lepäntalo 
et al., 2011). It therefore places a  socio-economic burden on the patients and enormous 
financial strain on health care systems worldwide (Frykberg and Banks, 2015).  
Acute wounds involve the co-ordinated activation of several different cell types by paracrine 
factors to progress through all the stages of wound healing (Fig. 2.4 A). In chronic wounds, 
the onset of the inflammatory phase is initially delayed but once it commences, inflammation 
is persistent and the wound is unable to progress into the proliferative and remodelling 
phases of healing (Landén et al., 2016). The continued presence of pro-inflammatory 
cytokines and destructive immune cells has numerous deleterious effects such as ECM 
degradation and impaired cellular migration/proliferation (Fig. 2.4 B) (Larouche et al., 2018).   
Inflammation is a vital process during wound healing that prepares the injured area for 
regeneration by preventing infection and removing cellular debris, however prolonged 
inflammation causes tissue damage. The accumulation of macrophages (M1) and 
neutrophils causes an increase in secretion of pro-inflammatory cytokines (Table 2.1) and 
chemokines that recruit even more immune cells. The increase in infiltration of immune cells 
cause excessive ROS production within the wounded area leading to destruction of cellular 
membranes, ECM components and can cause the onset of early senescence in cellular 
mediators of regeneration (Demidova-Rice et al., 2012). Tissue destruction is also caused 
by an increase in the secretion of serine proteases such as MMPs and neutrophil elastase, 
whilst tissue inhibiting metalloproteases (TIMPs) are downregulated (McCarty and Percival, 
2013). This results in a) the degradation of various growth factors (TGF-β and PDGF) and 
ECM components, b) reduction of fibroblast proliferation, c) a decrease in cell migratory 
ability and d) reduced collagen secretion (Zhao et al., 2016). Consequently, the debris from 
the degradation of ECM components attracts more immune cells that release additional pro-
inflammatory cytokines, thus generating a self-perpetuating pro-inflammatory cycle and 




Persistent inflammation and also bacterial infection are well-known phenomenon in chronic 
wounds during the late stages of healing (day 7 onwards) (Fig. 2.4 B)(Zhao et al., 2016, 
Frykberg, 1998). At this time a greater infiltration of neutrophils and monocytes is evident 
with subsequent increase in the cytokine and growth factor milieu (Larouche et al., 2018).  
However, little is known about the differences between acute and chronic wounds in the 
early stages (days 1-2) post injury. Thus, identifying the dysregulation early could greatly 
inform potential therapeutic strategies.  
Figure 2.4. Illustration of the various pathways, growth factors and cytokines involved in an acute and 
chronic wound. A) Acute wounds involve the co-ordination and activation of several different cell types and 
progresses through all stages of wound healing i.e. haemostasis, inflammation, proliferation and remodelling. 
Platelets fill the wound area and secrete TGF-β1 and PDGF which promote angiogenesis and activate 
fibroblasts to proliferate. Neutrophils and monocytes infiltrate. Neutrophil phagocytose debris and bacteria, 
degrades them via secretion of ROS and anti-microbial proteases. Monocytes differentiate into M1 
proinflammatory macrophages and secrete IL-1, TNF-α, TGF-β1, VEGF, PDGF and FGF, which promotes 
fibroblast activation and angiogenesis. Activated fibroblasts secrete collagen, fibronectin and other matrix 
proteins that result in the formation of granulation tissue. B) Chronic wounds are unable to progress from 
inflammatory phase of wound healing into the proliferative and remodelling phases resulting in a build-up of 
pro-inflammatory cytokines, MMPs and ROS which has numerous deleterious effects such as ECM 




2.2.1 Neuropathy as underlying cause for non-healing diabetic wounds 
Prior to the development of a diabetic foot ulcer, the pathogenesis of T2DM induces lower 
limb ischemia and neuropathy (Frykberg, 1998). The dysregulation of glucose metabolism 
(hyperglycaemia) and subsequent accumulation of AGEs leads to the hyper-glycosylation 
of tissues for long periods of time, which in turn causes oxidative stress-associated cellular 
damage (Wieman, 2005).  
Normal wound healing requires the production of low levels of ROS  by nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase enzymes (Jiang et al., 2011).  ROS plays a role 
in both the destruction of invading bacteria through inflammatory cell recruitment and cell 
signalling via promoting angiogenesis and the proliferation and migration of fibroblasts and 
keratinocytes (Hoffmann and Griffiths, 2018).  In T2DM, hyperglycaemia and increased 
glycolysis cause a build-up in the mitochondrial electron transport chain. This increases 
superoxide production and consequently ROS levels become excessive. The oxidative 
dysregulation results in peroxidation of DNA, lipids and proteins leading to cellular apoptosis 
or senescence (Han et al., 2013, Cano Sanchez et al., 2018).  
The peripheral microvascular and nervous systems are particularly sensitive to this 
destructive microenvironment. The high levels of oxidative stress contribute to diabetic 
neuropathy through the build-up of free radicals within the neurons leading to cell death 
(Vincent et al., 2004). This causes decreased sensation and movement, initially affecting 
the longer nerve fibres within the lower limbs. With the onset and progression of neuropathy 
there is a decrease in the production of neuropeptides such as substance P.  
Neuropeptides are released by nerves and inflammatory cells in response to  environmental 
stressors (injury) and their main function is immune regulation (Pradhan et al., 2009). Of 
particular relevance to this study, is the role that substance P plays in initiating the wound 
healing cascade (refer to section 2.2.2 below) and that the dysregulation thereof is 
associated with the overproduction of NEP (enzyme that degrades substance P). Antezana 
et al. (2002) conducted a study to assess NEP activity in T2DM patients with neuropathy 
and chronic wounds. The authors observed higher NEP activity in the ulcer margins of 
chronic wounds in diabetic patients (47.54±17.18 pmol MNA per h per μg) compared to the 
skin of healthy controls (3.42±1.84 pmol MNA per h per μg) and suggested that diabetic 






2.2.2 Role of Substance P and Neutral Endopeptidase in wound healing 
Substance P  is an 11 amino acid long tachykinin neuropeptide (Arg-Pro-Lys-Pro-Gln-Gln-
Phe-Phe-Gly-Leu-Met-NH2) encoded by the TAC1 gene and is secreted by sensory nerve 
fibres during injury (Fig. 2.5) (Leal et al., 2015). It is responsible for the pain sensation 
experienced during wounding (Um et al., 2017) and plays a role in initiating the healing 
cascade (Pradhan et al., 2009). Substance P functions via its G-protein coupled receptor, 
NKR-1, located on the surface of fibroblasts, keratinocytes, immune, endothelial, epithelial 











Figure 2.5. Amino acid structure of Substance P. Substance P is an 11 amino acid long hydrophobic 
neuropeptide found in the central nervous system and is responsible for assisting in the wound healing process 
by binding with high affinity to its receptor Neurokinin 1 receptor (NKR-1). 
 
In response to injury, substance P binds to its receptor and mediates wound healing through 
a series of downstream signalling events depending on the target cell type. Endothelial cells 
respond to substance P by acting as attractants and upregulate the infiltration of leukocytes 
to the injured area (Pernow, 1983). Subsequently, substance P promotes vasodilation and 
cell adhesion between leukocytes and endothelial cells. The generation of the endothelial 
cell adhesions creates a platform for infiltrating immune cells (Pradhan et al., 2009). These 
leukocytes release pro-inflammatory cytokines. Substance P has also been shown to 
stimulate the secretion of IL-1β, IL-2, IL-6, IL-8 and TNF-α by  T-lymphocytes, macrophages 
and neutrophils (Delgado et al., 2003) and by doing so acts as a chemoattractant for 
additional neutrophils, lymphocytes, monocytes and fibroblasts (Pradhan et al., 2011). .  
Chronic diabetic wounds display reduced expression of substance P due to the lack of 
nerves in diabetic patients compared to non-diabetic patients in addition to the 




agent for the treatment of chronic wounds has therefore been investigated in various models 
(Table 2.2).  
In animal models of delayed healing where type1 diabetes mellitus (T1DM) is induced by 
administering either streptozotocin (STZ) or alloxan monohydrate to destroy pancreatic 
function (Lukačínová et al., 2013), topical application of substance P onto the wounded 
areas has shown promising results (Table 2.2). In STZ-induced diabetic Wistar rats, 
substance P treatment resulted in decreased wound closure time, decreased MMP-9 
expression, increased release of growth promoting factors such as VEGF, TGF-β1, IL-10, 
improved proliferation of fibroblasts, increased angiogenesis and greater collagen 
deposition (Kant et al., 2013, Kant et al., 2015, Kant et al., 2017). In a STZ-induced diabetic 
mouse model, substance P has also been shown to improve corneal epithelial wound 
healing, mitochondrial function and it increased ROS scavenging capacity (Yang et al., 
2014). 
Similarly, in T2DM animal models (db/db mice, T2DM and Goto-Kakizaki rats) substance P 
treatment significantly improved wound healing. In db/db wound models, substance P 
treatment promoted  angiogenesis, cell proliferation, improved wound closure time, re-
epithelialisation, nerve fibre density, collagen deposition and increased inflammatory cell 
density (Um et al., 2017, Younan et al., 2010, Scott et al., 2008, Gibran et al., 2002). These 
findings are supported by ex vivo studies utilizing dermal fibroblasts isolated from db/db 
mice to investigate the effect of substance P. Jung et al. (2016) demonstrated that substance 
P treatment increased fibroblast proliferation, VEGF expression, angiogenesis promoting 
factors and could thus function to improve wound contraction (Jung et al., 2016). In a similar 
study, the co-culture of dermal db/db fibroblasts and bone marrow-derived macrophages in 
the presence of substance P resulted in M2 polarization of macrophages, improved 
fibroblast migration and induced cytokine release from macrophages and fibroblasts (Ni et 
al., 2016).  
Taken together, these studies emphasise the role and importance of substance P in 
wounding healing (Table 2.2). Substance P has been shown to increase angiogenesis, 
fibroblast proliferation and migration, increase the secretion of VEGF, TGF-β, pro- 
inflammatory cytokines, induce polarization of macrophages to M2 phenotype, improve 
wound closure and improve collagen deposition during the different stages of healing. 
Hence a decrease in its expression during distress (injury) results in severe impairment in 





Table 2.2: Substance P in human diabetic wounds and animal models 
 
Wound model Method/treatment Outcomes references 
Animal models    
T1DM   
streptozotocin-induced 
diabetic Wistar rats 
Topical application of 400 
µL of SP (10-6M)  
Wound closure by day 14. Increased 
levels of IL-10, VEGF and TGF-β. 
Decreased expression of MMP-9, IL-
1β and TNF-α. 
(Kant et al., 
2015) 
streptozotocin-induced 
diabetic Wistar rats 
SP (0.5 × 
10−6M) + curcumin (0.15%) 
were topically applied once 
daily for 19 days 
SP + curcumin combination on 
excision skin wound accelerated the 
wound healing. Wound closure was 
observed in day 19. 
(Kant et al., 
2017) 
streptozotocin-induced 
diabetic Wistar rats 
Topical application of SP 
solution (10-7M) 
Wound closure by day 14. Increased 
levels of VEGF and TGF-β. Improved 
fibroblast proliferation with collagen 
deposition and angiogenesis. 
(Kant et al., 
2013) 
streptozotocin-induced 
diabetic Wistar rats 
self-assembled peptides 
(SAPs)+ SP 200:7 (vol/vol) 
SAP +SP combination on excision skin 
wound accelerated the wound healing 
enhanced collagen deposition, and 
increased angiogenesis. Wound 
closure was observed after 3 weeks. 
(Kim et al., 
2018) 
streptozotocin-induced 
diabetic ICR male mice 
Treatment with SP (5 
nmol/kg) 
Decreased chronic inflammation, 
induced angiogenesis.   
(Park et al., 
2016) 
alloxan monohydrate -
induced diabetic New 
Zealand White rabbits  
qRT-PCR to quantitate and 
compare levels of 
peripheral cytokine (IL-6 
and IL-8) and neuropeptide 
(SP). 
Increased gene expression of IL-6 and 
IL-8 and a decrease in SP precursor. 
Observed a dysregulation of 
neuropeptide expression (SP) and 




diabetic C57BL/6J WT 
mice 
Treatment with 32 μg per 
90 μL of SP 
WT diabetic mice had reduced SP 
expression. Treatment with SP 
induced an acute inflammatory 
response causing wound to move into 
proliferative phase II of healing, 
activation of macrophages to M2 
phenotype, reduced MMP-9 
expression and wound closure was 
observed at day 10.  
(Leal et al., 
2015) 
streptozotocin-induced 
diabetic C57BL/6 male 
mice  
topical SP application, 5 μL 
SP (1 mmol/L) on the 
corneal surface 
Promoted corneal epithelial wound 
healing, improved mitochondrial 
function and increased ROS 
scavenging capacity.   
(Yang et al., 
2014) 
BALB/C-nu (nude mice) Treated with Skin-derived 
precursors (SKPs) 
SKPs promoted wound healing via cell 
proliferation, nerve fiber regeneration 
and the release of neuropeptides (SP). 
(Shu et al., 
2015) 
Sprague-Dawley rats Treatment of SP (10-7) 
mol/L combined with 
epidermal stem cells (ESC) 
injected into wound 
margins and middle of 
wound. 
Wound closure observed on day 14. 
Improved collagen deposition and 
nerve regeneration.  
(Zhu et al., 
2012) 
Sprague-Dawley rats Treatment with epidermal 
stem cells and substance P 
Wound closure observed at 14 days 
and increased nerve regeneration and 
wound healing. 





Wound model Method/treatment Outcomes references 
T2DM    
type 2 diabetic mice 
(db/db mice) 
SP injection (10 nM/kg, 
subcutaneously) 
Enhanced angiogenesis, increased 
cell proliferation. Observed the same 
wound closure after 7 days. 
(Um et al., 
2017) 
type 2 diabetic Goto-
Kakizaki (GK) male rats 
changes in expression of 
neuro- and angiotrophic 
mediators and receptors in 
intact and healing Achilles 
tendon via (qRT-PCR) 
NGF (upregulates SP expression) was 
down regulated resulting in diabetic 
rats causing a decrease neuropeptide 
expression (SP) and angiogenesis. 
(Ahmed et al., 
2017) 
Dermal fibroblasts from 
db/db mice co-cultured 
with bone marrow-derived 
macrophages 
Cells were treated with SP 
(10 nM) 
Promoted the migration of fibroblasts, 
M2 macrophage polarization and 
release of pro-inflammatory cytokines 
by fibroblasts and macrophages. 
(Ni et al., 
2016) 
    
Dermal fibroblasts from 
db/db mice 
Treatment with SP (100nM)  Increased proliferation of fibroblasts, 
increased expression of VEGF – 
increase in angiogenesis promoting 
factors and wound contraction.  
(Jung et al., 
2016) 




An increase in epidermal and dermal 
nerve fibre density and SP expression.  
(Younan et al., 
2010) 
type 2 diabetic mice 
(db/db mice) 
Topical application of 10-9 
M SP 
Increased early inflammatory cell 
density.  
(Scott et al., 
2008) 




(PEG) and SP 10-9 M 
SP promoted re-epithelialization. 
Wound closure observed by day 45. 
(Gibran et al., 
2002) 




HMEC-1 cells treated with 
10−4 mol/L SP followed by 
treatment with high levels 
of glucose and fatty acids 
(observed in DMII) to 
assess migration and 
proliferation  
SP treated cells without glucose and 
fatty acid treatment had increased 
levels of proliferation. The glucose and 
fatty acid treatment group showed 
significant impairment in cell migratory 
ability. 
(Wang et al., 
2009) 
 
Abbreviations: SP, Substance P; IL, Interleukin; MMP-9, Matrix metalloprotease-9;TNF-α, Tumour necrosis factor-
α; TGF-β: Transformation growth factor beta; SAP, self-assembled peptides;  qRT-PCR, quantitative real-time 
reverse-transcriptase polymerase chain reaction; NGF, nerve growth factor; VEGF,  Vascular endothelial growth 
factor; WT, wild type and ROS, reactive oxygen species; ESC: Epidermal stem cells; SKP: Skin derived precursors; 
PEG: Polyethylene glycol; HMEC-1, Human microvascular endothelial cell.  
 
2.2.3 Dysregulation of NEP in non-healing diabetic wounds. 
NEP is a thermolysin-like zinc metalloprotease that plays an essential role in the regulation 
of peptide signalling on the cell surface. It is located on the membrane of the same cells that 
express the NKR-1 receptor such as fibroblasts, keratinocytes, immune, endothelial, 
epithelial and smooth muscle cells and is anchored to the cell membrane via its hydrophobic 




NEP assists in various peptide metabolic regulatory processes in the cardiovascular, 
immune, inflammatory and nervous systems (Turner et al., 2001). These peptides include 
chemotactic peptides, enkephalins, natriuretic peptides and tachykinins (e.g. substance P). 
NEP regulates the expression of substance P by degrading it thereby hindering its biological 
function (Olerud et al., 1999). Once substance P binds to NEP, it competes with the NKR- 
1 receptor, substance P is then hydrolysed at the amino terminal between Gln6 – Phe7, Phe7 
– Phe8 or Gly9 – Leu10 residues to produce several degradation  products  (Figure 2.6) (Skidgel 
et al., 1984). 
 
Figure 2.6. Hydrolysis of hydrophobic residue Substance P by Neutral endopeptidase. Substance P is 
cleaved by NEP at the amino terminal between Gln6 – Phe7, Phe7 – Phe8 and Gly9 – Leu10 residues (Skidgel 
et al., 1984).  
 
The overexpression of NEP in chronic diabetic wounds is thought to be a contributing factor 
that prevents healing due to its high binding affinity to substance P.  There are many studies 
that support this hypothesis (Table 2.3).  
Diabetic (db/db) mice have been shown to have a 3 fold higher NEP enzyme activity than 
control mice (Spenny et al., 2002), and a significant increase in corneal wound healing has 
been demonstrated in NEP -/- mice compared to wild-type controls (Genova et al., 2018). 
Burssens et al. (2005), indicated that treatment of wounded Achilles Tendons in rats with 
substance P and a NEP inhibitor, increased fibroblast proliferation, angiogenesis and 
collagen deposition. Thus, providing further evidence for the role of NEP in delayed healing 




In a cell culture model, Muangman et al. (2003) showed that in the presence of high levels 
of glucose and fatty acids (as is the case in T2DM), NEP activity was increased in human 
microvascular endothelial cells (HMEC-1) and that treatment with vitamins were able to 
significantly reduce NEP enzyme activity. In patients (without neuropathy and diabetes 
mellitus), the assessment of NEP activity in acute wounds, unwounded skin and human 
derived skin cells indicated that NEP was expressed more in the migrating epithelial wound 
edges and first presented in the wound 6 hours post wounding (Olerud et al., 1999).   
Taken together, these studies reaffirm the importance of NEP regulation in wound healing 
and suggest that excessive NEP activity can lead to severe impairments in the healing 
process. NEP is thus an excellent candidate to use in designing a chronic wound model that 






















Table 2.3: Neutral endopeptidase in wound healing 
Wound model Method/treatment Outcomes references 
Animal models   
type 2 diabetic 
mice (db/db mice) 
NEP enzymatic 
activity assay 
Significantly higher activity (20.6pmol 
MNA/hr/µg) in skin of db/db mice 




(Spenny et al., 2002) 
 Treatment with NEP 
inhibitor (thiorophan 
25µM) 
Wound closure observed at day 18. 
NEP-deficient 
(NEP−/−) mice 
Alkali burn model of 
corneal injury 
Corneal wound healing was 
significantly increased in NEP−/− mice 
compared to the controls. 
(Genova et al., 2018) 
Sprague-Dawley 
rats  
Two treatments to 
wounded Achilles 
Tendon: 
SP 10-6 mol/kg body 
weight + NEP inhibitor 
or 
SP 10-6 mol/kg body 
weight + inhibitor  
Both treatments increased fibroblast 
proliferation, angiogenesis and 
collagen orientation.  










activity assay.  
NEP activity in the ulcer margins of 
diabetic patients was 47.54717.18 
pmol MNA per h per mg which was 
15.22 times higher than the control 
skin from patients without diabetes.  






Cells were first treated 
with high levels of 
glucose and fatty 
acids followed by 
treatment with 
Vitamins E and C 
NEP enzyme activity was upregulated 
in cells treated with high levels of 
glucose and fatty acids. Treatment 
with the vitamins blocked upregulation 
of NEP by glucose and fatty acids, 
NEP enzyme activity was significantly 
reduced. 






Cells were first treated 
with high levels of 
glucose and fatty 
acids followed by 
treatment with 
Vitamins E and C and 
N-acetylcysteine 
NEP gene expression was 
upregulated when cells were treated 
with high levels of glucose and fatty 
acids. Treatment with the vitamins 
blocked upregulation of NEP by 
glucose and fatty acids. 






NEP expression in 
wounded, unwounded 
skin and human 
derived skin cells 
NEP present 6 hours after wounding. 
NEP was expressed more in the 
migrating epithelial wound edges. 
NEP activity was detected in 
keratinocytes derived from human 
skin.  
(Olerud et al., 1999) 
 
Footnote: The table above contains animal and human diabetic wound models that either use or show the 
effect/ importance of NEP on wound healing. Abbr: NEP, Neutral endopeptidase; SP, Substance P; HMEC-




2.3 Current animal models: non-healing diabetic wounds  
There are currently various diabetic wound models that are commonly used such as the 
Rabbit ear ulcer model (Leal et al., 2015), the STZ-induced diabetic rat model (Kant et al., 
2015) and various mouse models (Healthy control C57Bl/6J mice fed a high fat diet, 
NONcNZ010, db/db, ob/ob mice and STZ-induced diabetic mice) (Table 2.4). Each of these 
models have advantages and disadvantages as summarized in Table 2.4.  
For a diabetic wound model, it is essential that the animal itself has a similar pathological 
profile and phenotype to T2DM patients. The NONcNZ010, db/db and ob/ob mice are 
therefore the most popular mouse strains used for diabetic wound studies and are readily 
available and supplied by Jacksons laboratories (Nunan et al., 2014, Elliot et al., 2018). 
NONcNZ010 are polygenic, insulin resistant mice with morbid obesity (Leiter et al., 2013). 
Fang et al. (2010) indicated that impaired healing of splinted wounds was evident in 
NONcNZ010 mice. This model has however sexual bias when it comes to diabetes and 
obesity development (Leiter et al., 2013). Db/db mice are diabetic leptin receptor deficient 
mice and become noticeably obese after 3 weeks of age. The db/db mice display delayed 
wound healing, increased metabolic efficiency, excessive hunger (constant eating), 
increased thirst and higher plasma insulin levels (Coleman, 1978). The one disadvantage of 
the db/db model is that these animals are born diabetic and therefore do not follow the same 
disease progression into diabetes as in human patients. The ob/ob mouse strain first 
become obese, insulin resistant and then develops T2DM, which is a similar progressive 
diabetic phenotype observed in human patients in a clinical setting.  
The ob/ob mice are pre-diabetic leptin deficient mice. The ob/ob mice exhibit obesity, 
delayed wound healing, insulin intolerance, hyperglycaemia, excessive hunger and 
increased thirst (Coleman, 1978).  Both the db/db and ob/ob strains are reproductively 
impaired and hence difficult to breed (Leiter et al., 2013). Nonetheless, these two strains are 










Table 2.4: Advantages and limitations of Diabetic wound models in animals 
Chronic wound 
Model 
Description Advantages Limitations 
Rabbit ear ulcer 
model 
Induces ischemic full 
thickness wounds by 
suturing and cutting of 
blood supply to wounded 
part of ear. 
• Low cytokine 
concentration post 
wounding. 
• High M1/M2 ratio. 
• Efficient in testing of 
pharmological agents.  
• Cheap to maintain. 
• Reproduce quickly. 
• Genetic variability 
between rabbit and 
humans. 
• Induction of neuropathy 





Induces diabetes by 
administration of 
streptozotocin which kills 
off pancreatic β cells. 
• Successful induction of 
diabetes. 
• Cheap to maintain. 
• Reproduce quickly. 
• Anatomical differences 
between Rat and human 
skin. 
NONcNZ010 mice Insulin resistant mice with 
morbid obesity.  
• Successful impairment 
of wound healing. 
• Sexual bias. 
Db/db mice Diabetic and leptin 
receptor deficient mice 
usually used in 
combination with 
additional factors that 
assist in delayed healing. 
• Cheap to maintain. 
• Reproduce quickly. 
• Easy to handle. 
• Impaired wound healing. 
• Difficult to breed due to 
sub-fertility. 
• Develop diabetes 
spontaneously. 
• Do not have the same 
progression into 
diabetes that we see in 
human patients. 
Ob/ob Mice Pre-diabetic Leptin 
deficient mice usually 
used in combination with 
additional factors that 
assist in delayed healing. 
• Cheap to maintain. 
• Reproduce quickly. 
• Easy to handle. 
• Shares exact phenotype 
of the development of 
diabetes as seen in 
patients. 
• Impaired wound healing. 
• Difficult to breed due to 
sub-fertility.  
Healthy control 
C57Bl/6J mice High 
fat diet model  
Healthy control mice fed a 
high fat diet to induce a 
diabetes-obesity 
syndrome. 
• Cheap to maintain. 
• Reproduce quickly  
• Slight delay in healing. 
• Pro-longed inflammation 




Footnote: The table above contains the advantages and limitations of diabetic animal wound models. Selected 
references using each chronic wound model (Leiter et al., 2013, Nunan et al., 2014, Elliot et al., 2018, Kant et al., 2015, 
Leal et al., 2015).  
 
Although these particular strains (db/db and ob/ob) exhibit delayed wound healing, they do 
not display the increased NEP levels observed in a chronic diabetic wound causing many 
therapeutic strategies that are successful in substandard animal models to fail in the clinical 
setting. There is thus a need for a chronic wound model that is able to overcome these 





Chapter 3 : Aims and Objectives 
It was hypothesised that administration of NEP to the margins of full-thickness excisional 
wounds, induced in obese pre-diabetic mice (B6.Cg-Lepob/J, ob/ob), would impair healing to 
such an extent that a chronic wound develops which resembles the phenotype of diabetic 
ulcers in the clinical setting. 
 
The aims and objectives of this study therefore included the following:   
 
Aim 1: Determine the optimum dose of NEP to be injected into the wound edges in an 
obese pre-diabetic mouse model (B6.Cg-Lepob/J, ob/ob) of delayed healing to create a 
chronic non-healing wound.  
Objective 1.1: Assess NEP enzyme activity (kinetic profile) within the wound tissue 
during the first 2 days post wounding following injection of various NEP 
concentrations.  
Objective 1.2:  Assess substance P expression within the wounded area and edges 
(immunohistochemistry) during the first 2 days post wounding following injection of 
various NEP concentrations.  
Objective 1.3: Assess MMP-9 expression in the wound tissue (enzyme-linked 
immunosorbent assay) during the first 2 days post wounding following injection of 
various NEP concentrations. 
Objective 1.4: Harvest and collect wound fluid on day 2 post wounding following 
injection of various NEP concentrations and determine the cytokine profile (multiplex 
bead array) within wound fluid. 
 
Aim 2: Investigate and compare the wound healing dynamics of a chronic non-healing 
wound in obese pre-diabetic mice (B6.Cg-Lepob/J, ob/ob), using the optimum NEP dosage 
injected into the wound edges, to an acute wound in wild-type mice (C57BL/6J) with saline 
treatment. 
Objective 2.1: Compare the macroscopic wound closure of the newly developed 




Objective 2.2: Compare the wound healing parameters of acute and chronic wounds 
by assessing granulation tissue formation, re-epithelialisation, cellularity and 
angiogenesis over a period of 7 days (histological analysis). 
Objective 2.3: Compare MMP-9 expression (enzyme-linked immunosorbent assay) 
within wound tissue of acute and chronic wounds over a period of 7 days. 
 
Aim 3: Investigate if there are differences in the protein profile of acute and chronic wounds 
during the early stages of wound healing. 
Objective 3.1: Compare the protein profile of acute and chronic wound tissue 2 days 









Chapter 4 : Materials and Methods 
4.1 Ethics Approval statement 
This study was approved by the animal research ethics committee at Stellenbosch 
University (SU-ACUD17-00016, 30 June 2017) and complied with the South African Animal 
Protection Act (Act no 71, 1962). All experimental procedures were conducted according to 
the ethical guidelines and principles of the declaration of Helsinki. The surgical procedures 
were performed only after authorization was granted by the South African Veterinary Council 
(SAVC). Refer to Appendix A for the ethical approval letters and proof of SAVC 
authorization. 
 
4.2 Overview of study design 
This study involved the induction of full-thickness dorsal excisional wounds on wild-type 
(C57BL/6J) and obese pre-diabetic (B6.Cg-Lepob/J, ob/ob) mice and was therefore 
classified as a high-risk study. Animal welfare was the main priority during the study and all 
relevant measures were taken to ensure that the animals did not suffer or experience any 
unnecessary pain and discomfort. Refer to Appendix B for the animal welfare monitoring 
sheet template and to Figure. 4.1 below for an overview of the study design.  The specific 
treatment groups and detailed methodology are described in sections 4.4-4.10.  All animal 
work, sample collection, processing and storage was conducted by Ms Boodhoo. 
Histological processing and staining (Masson trichrome stain, Haematoxylin stain and 
Immunohistochemistry for substance P) was performed by the Histology Lab, Department 
of Anatomy, Stellenbosch University. The microscopy and analysis of histology was done 
by Ms Boodhoo herself. All protein extractions and proteomic work was done by Ms. 










Figure 4.1. Study design. Phase I: Determination of the optimum concentration of NEP. B6.Cg-lepob/J 
(ob/ob) (>40 g) mice were wounded and treated with either Saline, low NEP (0.33 mg/µL), medium NEP (0.68 
mg/µL) or high NEP (1.02 mg/µL) immediately post wounding. Phase II: Comparison of the wound healing 
dynamics in Acute (wild-type C57BL6/J mice with saline treatment) versus the newly developed Chronic 
(B6.Cg-lepob/J (ob/ob) mice with optimum NEP treatment) wounds. Tissue samples were collected on days 




4.3 Animal housing & husbandry 
The animal research facility (Care and Use of Laboratory animals) at the Faculty of Medicine 
and Health Sciences (FMHS), Stellenbosch University, is equipped for the housing and 
husbandry of a variety of animal species and complies with accepted standards for the use 
of animals in research and teaching as reflected in the South African National Standards 
10386: 2008. The wild-type mice (C57BL/6J) were housed in this facility under standard 
conditions (12h light / 12h dark cycle at a controlled temperature of 21°C). The obese pre-
diabetic (B6.Cg-Lepob/J, ob/ob) mice were however not very active, and breeding was slow 
at 21°C; the temperature was therefore increased to 24°C which improved breeding 
outcomes. Animals had free access to drinking water and chow (Rat and Mouse Breeder 
Feed, Animal Specialties, Pty, Ltd., Klapmuts, SA). 
 
4.4 Procedures performed on the animals 
4.4.1 Induction of full thickness excisional wounds. 
Mice (a total of n=33 ob/ob; n=15 wild-type in Phase I and II) were weighed and anesthetized 
via an open system inhalation chamber (Fig. 4.2 A) using Isoflurane gas (3% for induction 
and 2% for maintenance) (Safeline Pharmaceuticals, South Africa). Dorsal hair was shaved, 
and the skin cleaned with povidone-iodine (Mundipharma, South Africa) prior to making two 
identical contra-lateral full-thickness skin excisions (Fig. 4.2 B-C). Excisional wounds were 
made by applying outward retraction of the skin using sterile forceps and the skin cut using 
sharp surgical scissors (Chen et al., 2013). Wounds (1 cm below the base of the skull and 
1 cm on either side of the midline) were approximately 6 mm2 in diameter and included 
removing of the underlying layers (panniculus carnosus) to achieve a full-thickness wound. 
Immediately after wounding, local anaesthetic, 7mg/kg lignocaine (2%) (Bodene, South 
Africa) was injected around the wound edges. Pain management was maintained for a 
period of 3 days by administering 300 mg/kg acetaminophen (Paracetamol 120 mg, South 
Africa) in the drinking water. Both excisional wounds were covered by a vapor-permeable 
polyurethane film (Hydro-film, Paul Hartmann AG, Germany). After recovery from the 
anaesthesia, mice were individually housed for a maximum period of 7 days and were 
monitored closely for signs of distress and pain to ensure the welfare of the animals. Refer 
to Appendix B for the animal welfare monitoring sheet template. 
During the optimization of the procedures it became clear that the obese pre-diabetic mice 




prolonged exposure (>10 min) and as consequence suffered from heart and respiratory 
failure. This is consistent with other reports in the literature (Gargiulo et al., 2012). To avoid 
this complication, mice were thus shaved and wounded on separate days in order to reduce 
the required time period under anaesthesia.  
Immediately post wounding, NEP (150 µL) was injected subcutaneously around the wound 
edges as indicated by the arrows in Figure 4.2 C. The ob/ob mice (n=24) were grouped into 
one of four treatment groups  
 Saline (control) (n=3 per time point)  
 Low NEP (0.33 mg/µL; enzyme activity:50 pmol/hour/ug) (n=3 per time point)  
 Medium NEP (0.68 mg/µL; enzyme activity:100 pmol/hour/ug) (n=3 per time point)  
 High NEP (1.02 mg/µL; enzyme activity:150 pmol/hour/ug) (n=3 per time point)  
The lowest concentration of NEP corresponds to the enzyme activity of NEP previously 
observed in the ulcer margins of diabetic patients by Antenzana et al. (2002). A dose 
response was however required, since mice have a higher metabolic turnover compared to 




Figure 4.2. Representative images of the wounding procedure. A) Open system inhalation chamber used 
to anesthetize animals. B) Illustration of shaved mouse with bilateral full thickness excisional wounds on the 
dorsal surface. C) Full thickness excisional wounds (day 0). The arrow heads indicate points around the wound 








4.4.2 Wound images and collection of wound fluid 
Images of the wounds were taken from directly above at three different time points (day 0, 
2 and 7) post wounding using a Canon digital camera (EOS 600D, Canon Inc., Taiwan). A 
ruler was placed horizontally along the wound edges in order to have a point of reference 
(scale = 1 cm) for assessment of macroscopic wound closure.  
Immediately prior to taking the wound images, wound fluid was collected using the needle 
puncture technique. The vapor-permeable polyurethane wound dressing was removed and 
100 µL of saline solution injected into the wound edges using a needle (25-30G, BD Micro-
Fine™ Plus, USA) and re-collected after approximately 30 sec. Dried wound exudate visible 
on the vapor-permeable polyurethane film was also collected using sterile tweezers and 
dissolved in the saline solution. The collected wound fluid was stored in Eppendorf tubes at 
-80º C for subsequent analysis. Prior to analysis, wound fluid was pooled together for each 
treatment group to ensure an adequate volume was available for analysis. 
 
4.4.3 Animal Euthanasia 
The wounded mice (n=34 ob/ob; n=10 wild-type) were euthanized on either day 0 and 2 in 
phase 1 or on day 0, 2 and 7 in phase 2 (Fig. 4.1). At the respective time points, all animals 
were anesthetized via an open system inhalation chamber using Isoflurane gas (3% for 
induction) and euthanized using cervical dislocation. The procedure was performed by a 
trained para veterinarian according to the SAVC guidelines. 
 
4.4.4 Harvesting of tissue and storage 
Immediately following sacrifice, the wounded tissue including a 5 mm margin was excised 
and processed for storage as follows: One half of each wound was snap frozen in liquid 
nitrogen (N2) and stored at -80ºC. These samples were used for protein extraction to assess 
MMP-9 expression, NEP enzymatic activity and the protein profile within the wounded 
tissue. The other half of each wound was fixed in 10% buffered formalin solution (10 mL 
37% formaldehyde solution, 0.8 g NaCl, 0.4 g Potassium phosphate monobasic, 0.65 g 
Potassium phosphate dibasic and 90 mL distilled water at pH 6.8) and embedded in paraffin 
wax for histological processing. Histological processing (section 4.9) and Figure 4.3 below 






Figure 4.3. Bilateral wounds on the dorsal surface of an obese mouse on day 0. The blocks surrounding 
the wound 1 and 2 indicates how both wounds were excised and halved into sections A and B. Section A for 
both wounds 1 and 2 were stored in 10% buffered formalin and section B for both wounds 1 and 2 were snap 
frozen in liquid nitrogen and stored at -80ºC. 
 
4.5 Determination of macroscopic wound size 
The surface area (mm2) for each wound was determined using Image J software (version 
1.46, NIH.gov, USA). Images were opened in Image J and the scale set according to the 
point of reference on each image. The straight-line tool was used to measure the number of 
pixels per 1 cm and the image scale set according to this measured distance. The free hand 
tool was used to trace around the wound edges and the surface area for each wound 
determined. Percentage wound closure over time was calculated using the following 
formula: 
% Wound closure = Wound area (day 0)−Wound area (day x)
Wound area (day 0)
 X 100 
 
4.6 Analysis of wound fluid 
Wound fluid collected on day 2 was analysed using the Bio-Plex Pro™ Mouse 23-plex bead-
array assay (M60009RDPD, Bio-Rad, USA) as per manufacturer’s instructions.   
Principle of the assay: This assay is a sandwich immunoassay that uses magnetic beads 
(Fluorescently dyed microspheres). The magnetic beads use antibodies that are directed 
against specific targets that are covalently bound to internally dyed beads. This permits for 
the distinction between various targets based on the colour emitted allowing the assessment 




Assay procedure: All assay components were supplied by the manufacturer and brought to 
room temperature before use. Beads (x 1 working solution of 50 µL) were added to each 
well and the plate incubated at room temperature with gentle agitation for 30 min after which 
it was washed twice with 100 µL wash buffer per well. Serial dilutions of known standards, 
a blank (background control) and the wound fluid samples (50 µL each) were loaded in 
duplicate wells of the 96 well plate. The plate was then incubated at room temperature with 
gentle agitation for 30 min followed by a washing step (three times with 100 µL wash buffer 
per well). Detection antibody (1 x working solution, 25 µL) was added to each well and 
incubated at room temperature for 30 min with gentle agitation followed by another washing 
step (three times with 100 µL wash buffer per well).  Streptavidin PE (50 µL) was then added 
to each well and incubated at room temperature for 10 min with gentle agitation. The plate 
was then washed again three times with 100 µL wash buffer per well. The beads within the 
plate, were then resuspended in 125 µL of assay buffer per well and the plate incubated at 
room temperature for 30 sec with gentle agitation. The plate was then read using a Luminex 
Bio-Plex 200 System (Bio-Rad; USA) at Low PMT, RP1 settings. All washing steps were 
performed using the automated plate washer (Bio-PlexTM Pro Wash Station; Bio-Rad, 
USA). Refer to Appendix C for the standard curves for all 23 cytokines assessed.  
 
4.7 NEP kinetic assay 
The enzymatic activity of NEP within the wound tissue was assessed using the Neutral 
endopeptidase Kinetic assay (K487-100, Bio vision, USA) according to the manufacturer’s 
instructions.  
Principle of assay:  This assay is based on the ability of NEP to cleave a synthetic substrate 
(Abz-based peptide) that is specific to NEP to produce a fluorescent product. This free 
fluorophore once cleaved can then be quantified using a fluorescent microplate reader via 
the following reaction:  
 
Assay procedure: Snap frozen tissue samples were homogenized in liquid nitrogen using a 
mortar and pestle and 100mg of each sample was weighed out into labelled Eppendorf 
tubes. Neutral endopeptidase Assay buffer (400 µL) containing 1 mM PMSF (1083709100, 
Sigma Aldrich, South Africa) and 10 μg/mL Aprotinin (A1153-5MG, Sigma Aldrich, South 




centrifuged at 4°C for 10 min at 12 000 x g. The supernatant was collected and stored at -
20°C for use in the kinetic assay. The protein concentration within each sample was 
determined using a NanoDrop™ 2000/2000c (Thermo fisher scientific, USA) (260/280 nm). 
The known NEP standards (0, 200, 400, 600, 800 and 1000 pmol/well), a positive control 
(NEP) and the extracted protein (6 µg) from each sample were loaded into duplicate wells 
of a 96 well plate. A background control for each sample was also run in duplicate (i.e. 
samples that did not receive the NEP substrate). The excitation and emission filters used to 
measure substrate development during the kinetic assay were 355 nm and 460 nm. 
Fluorescent intensity was measured at 10 min intervals over the course of 2 h (120 min) 
using a fluorometric multiplate reader (Fig. 4.4 A) (FLUOstar Omega, BMG LABTECH, 
Germany).  
End point (120 min) data analysis was performed as follows: The standard curve at 120 min 
(end point) was plotted on a graph with known NEP activity (pmol) of the standards on the 
x-axis and fluorescent intensity (RFU) on the y-axis (Fig. 4.4 B) to obtain the slope of the 
curve (ΔRFU/pmol). For each sample, the background reading was subtracted from the 
corresponding sample fluorescent reading at each time point to calculate the ΔRFU. The 





Sample NEP Activity = B/ (∆t X V) x D = pmol/min/mL = µU/mL 
Key:  
B = Abz from Standard Curve (pmol) 
∆t = Reaction time (min) 
V = Sample volume added into the reaction well (mL) 








Figure 4.4. NEP Kinetic assay. A) NEP enzyme activity over time illustrating the increase in fluorescent 
intensity over time for the positive control+ and wound tissue samples. B) Standard curve illustrating the 
quantification of NEP activity (0, 200, 400, 600, 800 and 1000 pmol/well) according to the fluorescent Ex/Em: 
330/430 nm readings at the 120 min end point. 
 
 
4.8 MMP-9 ELISA 
A sandwich MMP-9 ELISA (Enzyme-linked immunosorbent assay) kit (AB100732, Abcam, 
United Kingdom) was used to analyse the samples as per the manufacturer’s instructions. 
Extracted protein samples that were prepared for the NEP kinetic assay were also used in 
this assay.  
Principle of the test: The sandwich ELISA kit consists of a 96 well plate precoated with an 
antibody specific to MMP-9. Once the samples are loaded onto the ELISA plate, MMP-9 
binds to the target specific antibody forming an antigen-antibody complex. A secondary 
antibody conjugated to an enzyme then binds to the antigen-antibody complex. A substrate 
is then added and reacts with the secondary antibody’s conjugated enzyme to form a 
coloured detectable product.  


















































Procedure: The known recombinant MMP-9 standard was serial diluted to produce a dilution 
gradient ranging between 0 and 25 000 pg/mL. The standards   and samples (100 µL) were 
loaded into duplicate wells of the 96 well plate and incubated at 37˚C for 1 h 30 min. 
Following incubation, the samples and standards were aspirated from each well and 
Biotinylated anti-Mouse MMP-9 working solution (100 µL per well) added to the plate and 
incubated at 37˚C for 1 h. This was followed by washing the plate three times at room 
temperature with 350 µL wash buffer per well  for 2 min. HRP-Streptavidin 1 x working 
solution (100 µL per well) was added to the plate and incubated at 37˚C for 30 min followed 
by five washing steps (350 µL wells per well). TMB One-Step Substrate Reagent (90 µL per 
well) was added to the plate and incubated at 37˚C for 15 min to allow for the colour (blue) 
to develop in direct proportion to the amount of bound MMP-9 within each sample. The 
reaction was stopped by adding stop solution (50 µL per well) to the plate (colour changes 
from blue to yellow) and the absorbance was read immediately at 450 nm using a micro-
plate reader (Multiskan GO 1.00.40, THERMO-Scientific Group, USA). Due to a technical 
error, the standard curve failed to produce any colour, but the assay was successful for all 
the samples analysed. The results are therefore presented as Absorbance/ Optical density 
(OD) at 450 nm (Chapter 5). 
 
4.9 Histology and Immunohistochemistry. 
4.9.1 Tissue Processing & Paraffin wax embedding. 
Tissue samples preserved in a 10% buffered Formalin solution (10mL 37% formaldehyde 
solution, 0.8 g NaCl, 0.4 g Potassium phosphate monobasic, 0.65 g Potassium phosphate 
dibasic and 90 mL distilled water at pH 6.8) were processed within 2 weeks of harvest. 
Samples were transferred into labelled embedding cassettes and dehydrated in a series of 
70% Ethanol (EtOH) (30 min x1 repeats), 96% EtOH (30 min x2 repeats) and 99.9% EtOH 
(30 min x4 repeats). The dehydration steps were followed by Xylene (Kimix, South Afica) 
(30 min x2 repeats) and paraffin wax (SMM group, China) (60 min x 3 repeats).   
Tissue samples were removed from the cassettes, carefully orientated with the wound edge 
placed face down on a metal embedding mould and covered with melted Paraffin wax (SMM 
group, China) at 60°C (Leica EG1160 embedder, USA). The embedded samples were 
labelled and placed on a cold surface to allow the wax to set. Serial microtome sections (5 
µm) were made (Leica RM 2125 RT microtome, USA) and mounted onto labelled glass 




4.9.2 Haematoxylin & Eosin stain (histology) 
Wound tissue sections were stained for H&E to assess histological parameters (granulation 
tissue formation, angiogenesis, epithelialization and cellularity) using the Leica Auto Stainer 
XL. Haematoxylin is a blue nuclear stain and Eosin is a pink/ red stain that stains cytoplasm 
(light pink), collagen (pink), muscle (pink) and erythrocytes (red). 
Staining procedure: Tissue sections were incubated at 60°C for 2 min prior to 
deparaffinization (Xylene, 5 min x2 repeats). This was followed by a series of dehydration 
steps using 99% EtOH (2 min), 96% EtOH (2 min) and 70% EtOH (2 min). Tissue sections 
were then dipped in tap water (2 min) followed by staining with Haematoxylin stain (Kimix, 
South Africa) (8 min) at room temperature. Tissue sections were then rinsed in running water 
for 5 min to wash off excessive Haematoxylin staining solution before counter staining with 
Eosin (Kimix, South Africa) (4 min) at room temperature. Excessive Eosin staining solution 
was then rinsed off for 1 min using running tap water. Finally, the tissue sections were fixed 
with 70% EtOH (30 sec), 96% EtOH (30 sec) and 99% EtOH (30 sec) and the slides left to 
dry before mounting with coverslips using DPX mounting media (Sigma Aldrich, South 
Africa). Refer to Figure 4.5 A for a representative image of H&E staining.  
 
4.9.3 Image acquisition, data analysis and quantification  
The H&E stained tissue sections were used to quantify histological parameters such as 
granulation tissue formation, epithelialization and cellularity.  Tile scan images of the entire 
section were taken at 10x magnification using the Zeiss Axio Vision microscope (Zeiss Axio 
Observer 7 Inverted microscope, Zeiss, Germany) (Fig. 4.5 A). Assessment of the 
histological parameters was performed using Image J software (version 1.46, NIH.gov, 
USA).  
Images were opened in Image J. The straight-line tool was then used to measure the number 
of pixels that equates to 1 µm on the scale bar. This measured distance was then used to 
set the image scale. To determine the epithelial thickness (µm), the straight-line tool was 
used to measure distance by drawing 3 parallel lines through the thickness of the epithelium 
at both the wound edges and the newly formed epithelium within the wounded area (Fig. 4.5 
B). Similarly, the thickness of granulation tissue (µm) was determined by drawing 5 parallel 
lines through the granulation tissue within the wounded area (Fig. 4.5 B).  
The cellularity of the granulation tissue was determined by assessing the percentage area 




to an 8-bit grey scale and a region of interest (ROI) was drawn surrounding the granulation 
tissue within the wounded area by using the polygon selection tool.  The threshold was then 
adjusted to select all the blue stained cell nuclei as indicated in red in Figure 4.5 C. The 
percentage surface area within the granulation tissue (ROI) that represents nuclei were then 
measured as indication of cellularity.   
Figure 4.5. Representative images indicating identification of specific wound areas. A) Representative 
image of H&E staining indicating the wound edges and wounded area of an acute wound 7 days post 
wounding. B) Magnification of wound area illustrating the areas measured to assess epithelial thickness (µm) 
(black solid lines) and granulation tissue thickness (µm) (red lines). C) Illustration of the region of interest (ROI) 
(yellow outline) identified as granulation tissue within the wounded area. The threshold was set to identify the 
blue stained nuclei within the ROI. Image analysis was performed using Image J software.  
 
 
4.9.4 Masson Trichrome Stain (histology) 
Wound tissue sections were stained for Masson’s trichrome to assess scar formation, 
vascularization and collagen deposition. Masson trichrome stains collagen blue, nuclei black 
and the muscle, cytoplasm and keratin red.   
Staining procedure: Wound tissue sections were stained using the Leica Auto Stainer XL as 




deparaffinisation and dehydration as described in section 4.9.2. Samples were then dipped 
in tap water for 2 min and stained with Haematoxylin for 5 min. Samples were then placed 
in a filtered working solution of fuchsine ponceau-orange G (Sigma Aldrich, South Africa) for 
5-30 min before rinsing them in 0.2% Acetic Acid water. This was followed by a 5% 
phosphotungstic acid (Kimix, South Africa) solution for 5 min. Tissue sections were then 
stained with methanol green (Sigma Aldrich, South Africa) for 5 to 20 min and rinsed twice 
in 0.2% acetic acid water. Finally, the tissue sections were fixed with 70% EtOH (30 sec), 
96% EtOH (30 sec) and 99% EtOH (30 sec) and the slides left to dry before mounting with 
coverslips using DPX mounting media (Sigma Aldrich, South Africa). 
 
4.9.4.1 Image acquisition, data analysis and quantification:  
Tile scan images were taken of the entire Masson’s trichrome stained tissue sections at 10x 
magnification using the Zeiss Axio Vision microscope (Zeiss Axio Observer 7 Inverted 
microscope, Zeiss, Germany). Refer to Figure 4.6 A for a representative image of Masson’s 
trichrome staining. Assessment of the histological parameters was performed using Image 
J software (version 1.46, NIH.gov, USA). Images were opened in Image J. The straight-line 
tool was then used to measure the number of pixels that equates to 1 cm on the scale bar. 
This measured distance was then used to set the image scale.  
The Masson trichrome stained tissue sections were used to visualize collagen deposition 
within the wounded area and to count the number of blood vessels formed within the wound 




Figure 4.6. Representative images of histological analysis of Masson’s trichrome stained tissue 
sections. A) Representative image of M&T staining indicating the wound edges and wounded area of an acute 
wound 7 days post wounding. B) Magnified image of wound area illustrating collagen deposition (blue) in the 
wounded area in an acute wound 7 days post wounding and capillaries (indicated by black arrows) within the 
wounded area and wound edges. The black outlined illustrates a magnified image of a blood capillary within 
the granulation tissue of the wound area. 
 
 
4.9.5 Histology Scoring index 
The overall histology scoring index  was adapted from Galeano et al. (2001) and used as 






Table 4.1: Histological scoring index 
Scoring Feature 
1 ± Little epidermal and dermal organization 
(epithelial thickness < 30µm in wound area), few 
capillary vessels (<10), many infiltrated cells 
(<10%) and no granulation tissue formation. 
2 ± Moderate epidermal and dermal organization 
(epithelial thickness < 100µm in wound area), 
newly formed capillary vessels (>10%) in the 
entire wound area, granulation tissue (>100µm) 
3 ± Complete remodelling of the epidermis and 
dermis, well-formed capillary vessels. 
Footnote: Scoring parameters table adapted from Galeano et al. (2001). 
 
4.9.6 Substance P (Immunohistochemistry) 
Tissue sections were stained using standard immunohistochemistry (IHC) techniques to 
assess the expression of substance P within the wounded area and wound edges. This 
procedure was done in association with the histology laboratory at the Department of 
Anatomy and Histology, FMHS, Stellenbosch University using the Leica Bond Max Auto 
Stainer.  
Principle of the test: A primary anti-substance P antibody (ab10353, Abcam, United 
Kingdom) was used to bind to the substance P protein within the samples to form an antigen-
antibody complex. A secondary antibody (conjugated with alkaline phosphatase) then binds 
to this complex and a substrate is added that reacts with the enzyme conjugated to the 
secondary antibody to produce a brown coloured product. Refer to Figure 4.7 A for a 
representative image of substance P IHC staining. 
 
4.9.6.1 Image acquisition, data analysis and quantification:  
Tile scan images (3x3) were taken at 10x magnification using the Zeiss Axio Vision 
microscope (Zeiss Axio Observer 7 Inverted microscope, Zeiss, Germany) of each wound 
edge and the wound area. Assessment of substance P expression was performed using 
Image J software (version 1.46, NIH.gov, USA). Images were opened in Image J. The 
straight-line tool was then used to measure the number of pixels that equates to 1 µm on 
the scale bar. This measured distance was then used to set the image scale. The image 
was converted to an 8-bit grey scale and a region of interest (ROI) was drawn using the 




was then adjusted so that all the areas stained positive for substance P was selected as 
indicated in Figure 4.7 B. The percentage surface area stained positive within the wound 
and wound edges was then quantified.  
 
Figure 4.7. Immunohistochemistry of Substance P. A) Representative image indicating wound area and 
wound edges of a day 2 chronic wound. Area within the red outline box indicates positions that 3x3 tile scan 
images were taken at 10x magnification using the Zeiss Axio Vision microscope. B) Illustration of the region 
of interest (ROI) (yellow outline) identified as the left wound edge. The threshold was set to identify the 
positively stained areas (red highlight) of substance P. Image analysis was performed using Image J software. 
 
4.10 Proteomics 
The harvested wound tissue that was snap frozen in liquid N2 underwent a series of 
extractions and protein solubilisation steps to obtain a sufficient amount and quality of 




extraction processes were required. Refer to Figure 4.8 below for an overview of the tissue 
processing workflow.  
 
Figure 4.8. Flow chart of Tissue extraction for proteomic analysis. Tissue samples were homogenized in 
liquid nitrogen and 100 mg weighed out. Samples were then incubated for 1 h at 4°C in 89 % ethanol containing 
50 mM Tris(2-carboxyethyl) phosphine (TCEP), 1% acetic acid and 1 mg/mL caffeine standard. The 
supernatant was removed, and the tissue samples were sonicated for 15 min with methanol at 4°C. The 
supernatant was removed and incubated with 600 µL of methyl tert-butylether (MTBE) for 1 h at 4°C. Phase 
separation was induced by adding 100 mM triethylammonium bicarbonate (TEAB) to each sample and 
centrifuged for 14 min at 12 000 x g. Four volumes of methanol were added to the lower phase and centrifuged 
at 12 000 x g for 10 min. The supernatant was removed, and the pellet was sonicated for 10 min at 4°C with 
200 µL of 50 mM TEAB pH 7.8 containing 8 M urea, 0.5% SDS and a protease inhibitor cocktail. Four volumes 
of methanol were then added, and samples were centrifuged at 12 000 x g for 10 min. The supernatant was 





4.10.1 Tissue extraction 
Frozen tissue samples were homogenized to a fine powder in liquid nitrogen using a mortar 
and pestle at 4°C and 100 mg of each sample was weighed out into pre-weighed labelled 
glass vials. 300 mL of 89% ice cold ethanol containing 50 mM tris(2-carboxyethyl) phosphine 
(TCEP; Fluka, South Africa), 1% acetic acid (Sigma Aldrich, South Africa) with 1 mg/mL 
caffeine standard (Thermo Scientific, Pierce, South Africa) was then added to each sample. 
This was then followed by an incubation step at 4°C for 1 h. The supernatant was then 
removed and aliquoted into labelled pre-weighed 2 mL glass vials and stored at -20°C.  
Ice cold methanol (200 mL) was added to each tissue sample and sonicated for 15 min at 
4°C. The supernatant was removed using a flattened pipette tip and transferred into pre 
weighed glass vials and stored in -20°C. The next day the supernatant samples were thawed 
and 600 mL ice cold MTBE (Methyl tert-butyl ether, Sigma Aldrich, South Africa) was added 
and incubated for 1 h at 4°C.  
Phase separation was then induced by adding 154 mL of 100 mM% triethylammonium 
bicarbonate (TEAB, Sigma Aldrich, South Africa) with Halt protease inhibitor cocktail 
(Thermo Scientific, Pierce, South Africa). Samples were then centrifuged to separate phases 
12 000g x 14 min. Phases were not separating therefore additional 50 µl (x2) of diethylether 
was added to each sample and centrifuged for 1 min at 12 000 x g to induce phase 
separation. Phase separation was not observed after this step therefore samples were then 
stored at -20°C overnight to induce separation. The next day separation of phases was 
observed in all samples. The upper phase was removed and placed in pre-weighed 2 mL 
glass vials and stored at -20°C. 
The lower phase was removed and transferred to 2 mL Eppendorf microcentrifuge tubes. 
Four volumes of ice-cold methanol was added to the lower phase and incubated for 2 h at -
20°C to allow for precipitation of proteins out of solution. The Lower phase was then 
centrifuged at 12 000 x g for 10 min. Supernatant (metabolite fraction) was removed and 
placed in pre-weighed 2 mL glass vials and stored at -20 °C.  
To the extracted pellet, 200 mL 50 mM TEAB pH 7.8 containing 8 M urea (Sigma Aldrich, 
South Africa) and 0.5% SDS (Sigma Aldrich, South Africa) and protease inhibitor cocktail 
(Thermo Scientific, Pierce, South Africa) was then added and sonicated for 10 min at 4˚C. 
This was followed by a centrifugation step to bring solution down. Four volumes of ice-cold 




supernatant was removed and discarded, and the protein pellet was retained for proteomic 
analysis. 
 
4.10.2 Protein solubilisation 
To the protein pellets 50 mL 50 mM TEAB pH 7.8 containing 8 M urea and 0.5% SDS  were 
added and sonicated whilst intermittently vortexing until the pellet was dissolved. Each 
sample was then diluted 1:9 in deionized water. The remainder of the sample was then dried 
down in a Thermo Scientific™ SpeedVac™ Vacuum Concentrator for 1 h.  
 
4.10.3 Concentration determination 
A Bradford assay was performed to determine protein concentration within each sample. 
Bradford 1 x solution (10% Coommassie b.blue-G, 10% of 99% Methanol, 20% of 85% 
phosphoric acid and 70% distilled water) was made up and filtered. A BSA protein standard 
(Sigma Aldrich, South Africa) of 10 µL was aliquoted in the first row of the plate with protein 
concentrations ranging from 0 to 1 mg/mL and 10 µL of the 1:9 diluted samples were added 
to specific wells of the 96 well plate. Filtered Bradford reagent of 90 µL was added to each 
well and absorbance was read at 595 nm using a micro-plate reader (Multiskan GO 1.00.40, 
Thermo fisher scientific, USA). 
 
4.10.4 Second Tissue Extraction 
The skin structure did not open up properly therefore a higher detergent concentration was 
used in order to open up the structure.  
First Extract: Five volumes (500 µL) of 2% Triton X100 (%v/v), 4 M guanidine  hydrochloride 
in 25 mM 3-(N-morpholino) propanesulfonic acid pH 7.5 (MOPS, Sigma Aldrich, South 
Africa) containing 200 mM sodium chloride (Sigma Aldrich, South Africa), 5 mM TCEP and 
protease inhibitor cocktail was added to the remainder tissue extracts that were previously 
stored at -20°C. Proteins were extracted with intermittent sonication for 1 h at 4°C. The 500 
µL of supernatant was removed and this step was repeated for the remaining tissue at 4°C 




deionized water in order to remove any guanine from the remaining tissue. The supernatants 
collected from this step were combined to form Extract 1.  
Second Extract: The buffer used for the second extract was 3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonate 0.4%  m/v (CHAPS; Sigma Aldrich, South Africa) in 
MOPS,4 M Urea (Sigma Aldrich, South Africa) containing 200 mM sodium chloride (Sigma 
Aldrich, South Africa), 5 mM TCEP and protease inhibitor cocktail were added to the 
remainder tissue extracts from extract 1. Proteins were extracted with intermittent sonication 
for 2 h at 4°C. Supernatant was collected and this step was repeated for the remainder 
tissue. The supernatants were collected and combined to form the second extract. (No wash 
needed because 3rd extract contains SDS which is compatible with reagents in the 2nd 
extract) 
Third extract: Five volumes of 2% SDS in 100 mM sodium carbonate buffer pH 10 was 
added to remaining tissue from the second extract and incubated for 2 h at 4°C. The 
supernatant was collected. This step was repeated, and the supernatants were combined 
to form the third extract. 
Clean up: The first extract received ten volumes liquid: liquid extraction with hexane followed 
by 2 x five volume liquid: liquid extraction with hexane. A chloroform methanol clean-up was 
then performed. Briefly, 4 volumes of methanol (Romil, United Kingdom) was added to 100 
mL extract and vortexed vigorously before the addition of 100 mL chloroform (Merck, USA). 
The mixture was again vigorously vortexed before the addition of 300 mL deionized water. 
The sample was centrifuged at 12 000 x g to induce phase separation. The upper phase 
was aspirated without disturbing the protein wafer on the interphase. An additional 400 mL 
of methanol was added and the sample centrifuged to pellet the protein. This was done to 
prevent the Triton X100 from interfering with the Mass spectrometry analysis and 
trypsinisation. The second and third extracts received 2 x five volumes of hexane liquid: 
liquid clean up steps prior to chloroform methanol extraction.  
All the extracts (i.e. first, second and third) were then combined and a Bradford assay was 
performed as described previously to determine protein concentration.  
 
4.10.5 On-bead protein digestion 
All reagents are analytical grade or equivalent. Samples were re-suspended in 50 mM 




mM triscarboxyethyl phosphine (TCEP; Fluka, South Africa) in 50 mM TEAB for 1 h at 60°C. 
Cysteine residues were thiomethylated, with 20 mM S-Methyl methanethiosulfonate (Sigma 
Aldrich, South Africa) in 50 mM TEAB for 30 min at room temperature. After thiomethylation 
the samples were diluted two-fold with binding buffer (100 mM Sodium acetate, 30% 
acetonitrile, pH 4.5). The protein solution was added to MagResyn (Resyn Biosciences 
South Africa) HILIC magnetic particles prepared according to manufacturer’s instructions 
and incubated overnight at 4°C. After binding, the supernatant was removed and the 
magnetic particles washed twice with washing buffer (95% acetonitrile, CAN, Romil, United 
Kingdom). After washing the magnetic particles were suspended in 50 mM TEAB containing 
trypsin (New England Biosystems, USA) to a final ratio of 1:10. After a 6 h incubation at 
37°C the peptides were extracted once with 50 µL water and once with 50% acetonitrile 
(Romil, United Kingdom). The samples were dried down and re-suspended in 30 mL 2% 
acetonitrile: water; 0.1% Formic acid (FA; Sigma Aldrich, South Africa) 
Residual digest reagents were removed using an in-house manufactured C18 stage tip 
(Empore Octadecyl C18 extraction discs, Supelco, Sigma Aldrich, South Africa). The 
samples were loaded onto the stage tip after activating the C18 membrane with 30 mL 
methanol (Romil, United Kingdom) and equilibration with 30 mL 2% acetonitrile: water; 0.1% 
FA. The bound sample was washed with 30 mL 2% acetonitrile: water; 0.1% FA before 
elution with 30 mL 50% acetonitrile: water 0.1% FA. The eluate was evaporated to dryness. 
The dried peptides were dissolved in 2% acetonitrile: water; 0.1% FA for LC-MS analysis. 
 
4.10.6 Peptide quantification 
Samples were first dried in a concentrator for 3 h and resuspended in 30 µL of distilled water. 
A Pierce™ Quantitative Colorimetric Peptide Assay (Thermo fisher scientific, South Africa) 
was then performed as per manufacturer’s instructions. Standard solutions (20 µL each) 
were plated in the first row of the 96 well plate ranging from 0 to 50 mg/µL. The samples 
were then further diluted in a 1:1 ratio in 10 µL of distilled water and 20 µL of sample was 
added to specific wells in the 96 well plate. To each well 80 µL of working solution was 
added. The plate was then incubated at 37°C for 15 min then read at 480 nm using a micro-






4.10.7 Adding TMT tags to samples  
Tandem Mass Tag (TMT) tags (Thermo Scientific, Pierce, South Africa) were first brought 
to room temperature. Samples were dried in a concentrator for 3 h and resuspended in 10 
µL 100 mM TEAB at pH 8.0. The TMT tags were resuspended in 100% acetonitrile and 
vortexed twice for 30 sec each. Tags were then centrifuged briefly to pool solution together. 
Half the volume of the tags were each added to 14 µg of their respective samples as seen 
on Table 4.2. Samples containing tags were then incubated at room temperature for 2 h. An 
aliquot of the samples was taken for Quality control analysis and the rest were stored at -
80°C until further analysis. Refer to Figure 4.9 on how TMT tags bind to peptides and are 
able to distinguish between samples when they are detected simultaneously as a single and 
indistinguishable precursor ion peak. 
 
Figure 4.9. Theory of TMT tags. The tags consist of an MS/MS reporter group, a balancing arm and an amine 
reactive group (N- hydroxysuccinimide). The amine reactive group binds to the N- terminus of a peptide or to 
a lysine residue during labelling. Once labelled, all samples are mixed and analysed in a single liquid 
chromatography mass spectrometry (LC-MS) experiment. Because the isobaric tags possess the same 
chemical properties, all peptides from different TMT-labelled samples co-elute during LC separation. Once the 
peptides enter the mass spectrometer, they are detected simultaneously as a single and indistinguishable 
precursor ion peak. 
 
Table 4.2. Identification of TMT tag added to specific samples.  














4.10.8 First dimension High pH Reversed-Phase Peptide Fractionation  
A high pH Reversed-Phase Peptide Fractionation Kit (Thermo Scientific, Pierce, South 
Africa) was performed as per manufactures instruction to fractionate the digested samples 
containing the TMT tags before LC/MS analysis. The purpose of this first dimension 
reversed phase fractionation is to simplify the mixture prior to LC-MS/MS and remove the 
unbound TMT tags from the sample.  
Reversed-Phase Fractionation Spin Column containing 20 mg of resin in a 1:1 water/DMSO 
slurry was centrifuged at 5000 x g for 2 min to remove distilled water from column. The 
column was conditioned with 300 µL of 2% acetonitrile: water; 0.1% FA and centrifuged at 
5000 x g for 2 min twice. The column was then treated with 300 µL of 0.1% Trifluoroacetic 
acid (TFA, Thermo Scientific, Pierce, South Africa) and centrifuged at 5000 x g for 2 min 
twice.  
Digested samples were dried in a concentrator for 2 h leaving an oily residue. They were 
then combined, loaded on to Reversed-Phase Fractionation Spin Columns and centrifuged 
at 3000 x g for 2 min. The run through was collected and stored at -80°C. The column was 
then loaded with 300 µL of a gradient based step wise elution solutions with increasing 
acetonitrile (ACN): water; 0.1% TFA concentrations (5%, 10%, 12.5%, 15%, 17.5%, 20%, 
22.5%, 25% and 50% ACN respectively) and centrifuged at 3000 x g for 2 min after each 
elution solution was added. The follow through fractions were collected after each eluting 
step into labelled 1.5 mL Eppendorf’s.  Fractions were then dried overnight in a concentrator 
for further analysis on the LC/MS. 
 
4.10.9 Liquid chromatography 
Quality control analysis: Dionex nano-RSLC 
Liquid chromatography was performed on a Thermo Scientific Ultimate 3000 RSLC 
equipped with a 5 mm x 300 µm C18 trap column (Thermo Scientific, South Africa) and a 
nanoEase M/Z Peptide CSH 25cmx75µm 1.7 µm particle size C18 column (Waters, South 
Africa) analytical column. The solvent system employed was loading: 2% acetonitrile: water; 
0.1% FA; Solvent A: 2% acetonitrile: water; 0.1% FA and Solvent B: 100% acetonitrile: 
water. The samples were loaded onto the trap column using loading solvent at a flow rate 
of 2 µL/min from a temperature controlled autosampler set at 7°C. Loading was performed 




nL/min and the gradient generated as follows: 5.0% -35%B over 80 min using Chromeleon 
non-linear gradient 6; 30% -50% B from 80 -100. Chromatography was performed at 45°C 
and the outflow delivered to the mass spectrometer through a stainless-steel nano-bore 
emitter.  
 
4.10.10 Tandem Mass Tag analysis 
Liquid chromatography was performed on a Thermo Scientific Ultimate 3000 RSLC 
equipped with a 5 mm x 300 µm C18 trap column (Thermo Scientific, South Africa) and a 
nanoEase M/Z Peptide CSH 25 cm x75 µm 1.7 µm particle size C18 column (Waters, South 
Africa) analytical column. The solvent system employed was loading: 2% acetonitrile: water; 
0.1% FA; Solvent A: 2% acetonitrile: water; 0.1% FA and Solvent B: 100% acetonitrile: 
water. The samples were loaded onto the trap column using loading solvent at a flow rate 
of 2 µL/min from a temperature controlled autosampler set at 7°C. Loading was performed 
for 5 min before the sample was eluted onto the analytical column. Flow rate was set to 300 
nL/min and the gradient generated as follows: 5.0% -35%B over 130 min; 30% -50% B from 
130-150 min using Chromeleon non-linear gradient 6. Chromatography was performed at 
45°C and the outflow delivered to the mass spectrometer through a stainless-steel nano-
bore emitter. 
 
4.10.11 Mass spectrometry 
Quality control analysis: Mass spectrometry was performed using a Thermo Scientific 
Fusion mass spectrometer equipped with a Nanospray Flex ionization source. The sample 
was introduced through a stainless-steel emitter. Data was collected in positive mode with 
spray voltage set to 1.8 kV and ion transfer capillary set to 175°C. Spectra were internally 
calibrated using polysiloxane ions at m/z = 445.12003 and 371.10024. MS1 scans were 
performed using the orbitrap detector set at 120 000 resolution over the scan range 350-
1500 with AGC target at 4 E5 and maximum injection time of 50 ms. Data was acquired in 
profile mode. 
MS2 acquisitions were performed using monoisotopic precursor selection for ion with 
charges +2-+7 with error tolerance set to +/- 10 ppm. Precursor ions were excluded from 
fragmentation once for a period of 60 sec. Precursor ions were selected for fragmentation 




ions were detected in the orbitrap mass analyzer set to 30 000 resolution. The AGC target 
was set to 5E4 and the maximum injection time to 80 ms. The data was acquired in centroid 
mode.  
Tandem Mass Tag Analysis – first pass: Mass spectrometry was performed using a Thermo 
Scientific Fusion mass spectrometer equipped with a Nanospray Flex ionization source. The 
sample was introduced through a stainless-steel emitter. Data was collected in positive 
mode with spray voltage set to 1.8 kV and ion transfer capillary set to 175°C. Spectra were 
internally calibrated using polysiloxane ions at m/z = 445.12003 and 371.10024. MS1 scans 
were performed using the orbitrap detector set at 120 000 resolution over the scan range 
350-1750 with AGC target at 4 E5 and maximum injection time of 50ms. Data was acquired 
in profile mode. 
MS2 acquisitions were performed using monoisotopic precursor selection for ion with 
charges +2-+7 with error tolerance set to +/- 10 ppm. Precursor ions were excluded from 
fragmentation once for a period of 60 sec. Precursor ions were selected for fragmentation 
in HCD mode using the quadrupole mass analyser set at 0.7 m/z isolation width with HCD 
energy set to 38%. Fragment ions were detected in the orbitrap mass analyzer set to 50 000 
resolution. The AGC target was set to 1E5 and the maximum injection time to 105 ms. The 
data was acquired in centroid mode. 
Tandem Mass Tag Analysis – Second Pass: Mass spectrometry was performed using a 
Thermo Scientific Fusion mass spectrometer equipped with a Nanospray Flex ionization 
source. The sample was introduced through a stainless-steel emitter. Data was collected in 
positive mode with spray voltage set to 1.8 kV and ion transfer capillary set to 175°C. Spectra 
were internally calibrated using polysiloxane ions at m/z = 445.12003 and 371.10024. MS1 
scans were performed using the orbitrap detector set at 120 000 resolution over the scan 
range 350-1750 with AGC target at 4 E5 and maximum injection time of 50 ms. Data was 
acquired in profile mode. 
The targeted mass exclusion filter was populated using unambiguously assigned precursor 
m/z from the analysis of the first pass with a retention window of 1 min. MS2 acquisitions 
were performed on ions not excluded using monoisotopic precursor selection for ion with 
charges +2-+7 with error tolerance set to +/- 10 ppm. Precursor ions were excluded from 
fragmentation once for a period of 60 sec. Precursor ions were selected for fragmentation 
in HCD mode using the quadrupole mass analyser set at 0.7 m/z isolation width with HCD 




50 000 resolution. The AGC target was set to 1E5 and the maximum injection time to 125 
ms. The data was acquired in centroid mode. 
 
4.10.12 Data Analysis 
The raw files generated by the mass spectrometer were imported into Proteome Discoverer 
v1.4 (Thermo Scientific, South Africa) and processed using the Sequest and MSAmanda 
algorithms. Database interrogation was performed against a concatenated database 
created using uniprot Mus musculus database (reviewed entries only; 17461 entries) 
concatenated with the cRAP contaminant database (https://www.thegpm.org/crap/). Semi-
tryptic cleavage with 2 missed cleavages was allowed. Precursor mass tolerance was set to 
20 ppm and fragment mass tolerance set to 0.05 Da. Demamidation (NQ), oxidation (M) 
were allowed as dynamic modifications and thiomethyl of C, TMT-6 of K and n as static 
modification. Peptide validation was performed using the Target-Decoy PSM validator node. 
The results files were imported into Scaffold 1.4.4 and identified peptides validated with the 
Peptide and Protein Prophet algorithms included in Scaffold. Reporter ion extraction was 
also performed by Scaffold. 
A cut off of 1.5 fold difference between the acute and chronic groups was considered a good 
way to identify proteins of interest to investigate further. The identified proteins were then 
inserted into STRING (Szklarczyk et al., 2019) (freely available biological data base cite: 






Chapter 5 :  Results 
5.1 Phase I: Determination of optimum NEP concentration for chronic wound 
induction.  
5.1.1 Animal welfare during the early stages (2 days) post wounding 
For day 0 sample collection, full-thickness excisional wounds were made on a total of 17 
obese pre-diabetic (B6.Cg-Lepob/J, ob/ob) mice (>40 g, 10-14 weeks old) [treatment 
groups: Saline (n=4), Low NEP (n=4), NEP medium (n=4) and NEP high (n=5)]. During the 
optimization of the surgical procedures, an initial survival rate of 83% was observed (3 died) 
and samples from these animals were excluded and not counted in the n=28. NEP treatment 
had no effect on the survival rate of the animals, instead prolonged exposure to anaesthesia 
(> 20 min) resulted in respiratory problems and heart failure in the ob/ob mice. To avoid this 
adverse effect, animals were shaved a day prior to wounding in order to limit the required 
period under anaesthesia. Following this adjustment, an additional 14 obese-prediabetic 
mice were wounded [treatment groups: Saline (n=3), low NEP (n=3), medium NEP (n=3) or 
high NEP (n=5)] and tissue harvested on day 2 post wounding.  
For each animal, a wellness score was calculated based on appearance and behaviour 
during the initial 2 days post wounding and treatment (Refer to Appendix B for the animal 
welfare monitoring sheet template and scoring parameters). No significant difference was 
observed in appearance and behaviour of the animals within the different treatment groups 
with scores ranging between 1 and 2 (Fig. 5.1 A-B). During this initial phase following 
wounding, animals were slightly less attentive and interactive than before wounding 
however, no significant differences were observed between day 0 to 2. Pain management 
in the form of locally applied lignocaine and oral acetaminophen did however ensure that 
animals were able to feed normally. No difference was observed in appearance and 
behaviour comparing the NEP groups to the control saline group or between the different 
treatment groups. There were no significant differences in body weight (g) between day 0 
(Saline 49.22 ± 1.30 g; low NEP 46.29 ± 2.31 g, medium NEP 44.68 ± 0.95 g, high NEP 
44.98 ± 1.46 g) (mean ± SE g) and day 2 (Saline 45.93 ± 0.26 g; low NEP 40.63 ± 0.66 g, 
medium NEP41.35 ± 2.21 g, high NEP 42.53 ± 1.79 g) within the treatment groups (Fig. 5.1 
C). No significant difference was observed between the treatment groups on both day 0 and 





Figure 5.1. Animal wellness during the initial 2 days post wounding. Animal (B6.Cg-Lepob/J, ob/ob) 
wellness was measured over a period of 2 days post wounding by assessing A) Appearance, B) Behaviour 
and C) body weight. For the treatment groups either Saline (n=3), low NEP concentration (0.33 mg/µL, n=3), 
medium NEP concentration (0.68 mg/µL, n=3) or high NEP concentration (1.02 mg/µL, n=5) were injected 
around the wound edges immediately after injury.  A) Animal wellness: Appearance. The Appearance score 
was assigned as follows: 1 – Well groomed, no discharges/ lesions and normal breathing/ posture; 2 – rough 
coat, slight discharges/lesions and abnormal breathing and 3 – very rough coat, noticeable discharges/ lesions 
and definite difficulty breathing.  B) Animal wellness: Behaviour. The behaviour score was assigned as follows: 
1 – attentive, inquisitive, interactive and normal walk/pace; 2 – not very interactive, less attentive, less active 
and abnormal walk/pace and 3 – not active, unresponsive. C) Animal weight (g) was measured on day 0 pre-
wounding and on day 2 post wounding. Statistical analysis: Factorial ANOVA with Tukey’s post hoc test, 













































































5.1.2 Wound edge NEP enzymatic activity at 2 days- post wounding. 
Firstly, there were no significant differences in NEP activity in saline control (892 ± 153 pmol) 
(mean ± SE) versus low NEP (665 ± 99 pmol), medium NEP (750 ± 61 pmol)  and high NEP 
(909 ± 104 pmol) treatments on Day 0 (Figure 5.2). A similar result was obtained on Day 2, 
with no significant differences between saline (286 ± 52 pmol), low NEP (389 ± 33 pmol), 
medium NEP (282 ± 58 pmol) and high NEP (301 ± 29 pmol) treatment groups (Figure 5.2). 
A significant effect of time (p<0.001) was evident in all four treatment groups with NEP 
activity being higher on day 0 compared to day 2, Saline: x3 fold higher, low NEP: x1.7 fold 
higher, medium NEP: x2.7 fold higher and high NEP: x3 fold higher. No difference could 
however be detected in NEP activity between treatment groups at the same time point (Fig.  
5.2). 
 
Figure 5.2. NEP enzymatic activity. NEP enzyme activity was measured in kinetic mode over a period of 120 
min in 6 µg of protein extracted from wound tissue (n=3 biological repeats per group). Statistical analysis: 
Repeated measures ANOVA with Tukey’s post hoc test. *p<0.001 indicate significant effect of time.  
 
5.1.3 The expression of substance P within the wounded area and wound edges during the 
early stages (2 days) post wounding within each treatment group. 
The expression of substance P was quantified as the percentage surface area stained 
positive within either the wounded area or the wound edges for each treatment group (Fig.  
5.3-5.4).  Within the wounded area, a significant effect of time (p<0.01) was evident with an 
increase from day 0 to day 2 in substance P staining in all treatment groups, Saline: x6 fold 
































increase (Fig. 5.3 A). There were no significant differences in substance P expression in the 
wound area between treatment groups on day 0, saline (1.6 ± 0.45%) (mean ± SE %), low 
NEP (2.6 ± 0.5%), medium NEP (1.6 ± 0.26%) and high NEP (1.5 ± 0.38%). On day 2, a 
greater percentage (x2 fold higher) (p<0.05) of the wound area stained positive for 
substance P in the animals treated with a low concentration of NEP (15 ± 3.76%) compared 
to the high concentration (7.1 ± 1.44%) (Fig. 5.3 A). Medium concentration (7.1 ± 2.29%) 
did not differ significantly between saline (9.3 ± 2.08%), low and high NEP treatments within 
the wound area on day 2. In the wound edges, no difference could be detected in substance 
P staining between treatment groups at the same time point (Fig. 5.3 B). Representative 
IHC images are shown in Figure 5.4. 
 
 
Figure 5.3. Substance P expression in wound area and wound edge (% surface area). Positive IHC 
staining for Substance P was assessed in A) Wound area and B) Wound edges on days 0 and 2 post 
wounding.  For the treatment groups either Saline (n=3), low NEP concentration (0.33 mg/µL, n=3), medium 
NEP concentration (0.68 mg/µL, n=3) or high NEP concentration (1.02 mg/µL, n=5) were injected around the 
wound edges immediately following injury. Statistical analysis: Factorial ANOVA with Tukey’s post hoc test.  


































































Figure 5.4. Representative IHC images of Substance P staining. Histological cross sections were stained 
with an anti-Substance P antibody (Immunohistochemistry) and an eosin stain. Images (tile scan) were 
acquired at 10x magnification indicating wound area (black dotted line) and wound edges (red arrows). For the 
treatment groups either Saline (n=3), NEP low (n=3), NEP medium (n=3) or NEP high (n=5). were injected 




5.1.4 The high dose of NEP (1.02 mg/µL) injected around the wound edges on day 0 
increased MMP-9 expression two days post wounding.   
Tissue MMP-9 expression on day 0 and 2 post wounding was determined using an ELISA 
assay in all treatment groups. Sample harvested immediately post injury (day 0) revealed 
no difference in MMP-9 expression between the treatment groups, saline (0.298 ± 0.1 OD) 
(mean ± SE OD), low NEP (0.302 ± 0.03 OD), medium NEP (0.209 ± 0.15 OD) and high 
NEP (0.453 ± 0.12 OD) (Fig. 5.5). A significant increase (x2.3fold, p<0.05) in tissue MMP-9 
expression was however evident on day 2 post wounding in the animals treated with a high 
concentration of NEP (0.479 ± 0.04 OD) compared to saline (0.211 ±0.01 OD) at the same 
time point. No significant differences were seen on day 2 between saline control, low (0.143 
± 0.01 OD) and medium (0.093 ± 0.23 OD) NEP treatments (Fig.5.5). There were no 
differences observed between day 0 and day 2 for all the treatment groups. 
Figure 5.5. Tissue MMP-9 expression during the first two days post wounding. Wound tissue was 
collected (n=3 mice per treatment group, x2 wounds per animal) and total protein extracted (0.25mg/µL) from 
these samples to determine MMP-9 expression levels. Treatment groups: Saline (vehicle control), low NEP 
concentration (0.33 mg/µL), medium NEP concentration (0.68 mg/µL) or high NEP concentration (1.02 mg/µL).  
Statistical analysis: Factorial ANOVA with Tukey’s post hoc test. *p<0.05 indicates significant differences 
between groups at the same time point. NOTE: Known standards were not included onto the assay, therefore 
quantification in terms of pg/mL were unfortunately not possible. Values are thus presented as absorbance 
read (OD450nm). 
 
5.1.5 Wound fluid: The high dose of NEP (1.02 mg/µL) injected around the wound edges 
on day 0 decreased cytokine levels 2 days post wounding 
Wound fluid was collected on day 2 post wounding for all treatment groups and the cytokine 
profile of 10 pro-inflammatory cytokines; 7 chemokines and 5 anti-inflammatory cytokines 






































to the small volume of wound fluid collected from each animal, all biological repeats (n=3) 
for the same treatment group were pooled together prior to analysis. Compared  to  saline,  
treatment  with  a  high  concentration of NEP induced an overall decrease (> 2-fold) in the 
levels of pro-inflammatory cytokines (IL-1β, IL-6, IL-9, IL-12p40, IL-12p70, IL-17, IFNγ), 
chemokines (Eotaxin, G-CSF, GM-CSF, KC, MIP-1α, MIP-1β) and anti-inflammatory 
cytokines (IL-2, IL-3, IL-4, IL-5, IL-10, IL-13). Refer to table 5.1.  
Table 5.1: Cytokine Profile of day 2 wound fluid comparing pooled samples from saline versus pooled 
samples of each individual NEP group.  
 ob/ob 
 Saline NEP low NEP medium  NEP high 
 pg/mL (set=1) pg/mL fold change pg/mL fold change pg/mL fold change 
Proinflammatory              
IL-1α 266 (1,0)  280 (1,1) - 587 (2,2) ↑ 219 (0,8) - 
IL-1β 54 (1,0)  37 (0,7) - 88 (1,6) - 19 (0,4) ↓ 
IL-6  2672 (1,0)  2702 (1,0) - 3569 (1,3) - 873 (0,3) ↓ 
IL-9  11 (1,0)  4 (0,4) ↓ 7 (0,6) - 6 (0,5) ↓ 
IL-12(p40)  84 (1,0)  100 (1,2) - 171 (2,0) ↑ 45 (0,5) ↓ 
IL-12(p70)  227 (1,0)  116 (0,5) ↓ 186 (0,8) - 97 (0,4) ↓ 
IL-17  8 (1,0)  2 (0,3) ↓ 7 (0,8) - 2 (0,3) ↓ 
IFN-γ 13 (1,0)  5 (0,4) ↓ 8 (0,6) - 6 (0,5) ↓ 
RANTES  72 (1,0)  128 (1,8) - 96 (1,3) - 73 (1,0) - 
TNF-a  106 (1,0)  59 (0,6) - 241 (2,3) ↑ 56 (0,5) ↓ 
             
Chemokines              
Eotaxin  630 (1,0)  604 (1,0) - 487 (0,8) - 226 (0,4) ↓ 
G-CSF  10425 (1,0)  7357 (0,7) - 17277 (1,7) - 5200 (0,5) ↓ 
GM-CSF  45 (1,0)  22 (0,5) ↓ 35 (0,8) - 16 (0,3) ↓ 
KC  5031 (1,0)  3402 (0,7) - 7085 (1,4) - 1258 (0,3) ↓ 
MCP-1  10444 (1,0)  6812 (0,7) - 13694 (1,3) - 5858 (0,6) - 
MIP-1α 1115 (1,0)  714 (0,6) - 5308 (4,8) ↑ 436 (0,4) ↓ 
MIP-1β 1336 (1,0)  901 (0,7) - 2005 (1,5) - 555 (0,4) ↓ 
             
Anti-inflammatory            
IL-2  5 1,0  2 (0,4) ↓ 4 (0,7) - 3 (0,6) - 
IL-3  7 1,0  4 (0,5) ↓ 4 (0,6) - 3 (0,5) ↓ 
IL-4  16 1,0  1.09 (0,07) ↓ 9 (0,5) ↓ 0.27 (0,02) ↓ 
IL-5 8 1,0  3 (0,3) ↓ 4 (0,5) ↓ 3 (0,4) ↓ 
IL-10  45 1,0  21 (0,5) ↓ 47 (1,1) - 22 (0,5) ↓ 
IL-13  116 1,0  73 (0,6) ↓ 89 (0,8) - 61 (0,5) ↓ 
 
Footnote: Cytokine profile was generated by analysing wound fluid collected on day 2 post wounding. Wound fluid 
was pooled for each treatment group and analysed using Bioplex 23 cytokine assay kit. Cytokine results are expressed 
in pg/mL and changes of more than 2 fold were indicated by ↑ (increase) and ↓ (decrease). Abbreviations: IL, 
interleukin; IFN- γ, interferon gamma; TNF-α, tumor necrosis factor alpha; GCSF, granulocyte colony-stimulating 
factor; GMCSF, granulocyte macrophage colony-stimulating factor; KC, keratinocyte chemoattractant; MCP, 




Taken together, the data from phase I suggests that the high concentration of NEP (1.02 
mg/µL) is needed to mimic some of the characteristics of a chronic wound during the early 
stages post wounding, namely overexpression of MMP-9 and delayed onset of inflammation. 
 
5.2 Phase II: Comparison of the wound healing dynamics between the Acute and 
newly developed Chronic wound models over a period of 7 days. 
The wound healing dynamics were compared in Acute (wild-type C57BL/6J mice: saline 
treatment) and Chronic (obese prediabetic B6.Cg-Lepob/J, ob/ob mice: optimum NEP 
treatment) wounds over 7 days. 
 
5.2.1 Animal welfare over a period of 7 days post wounding 
A significant difference was evident in the weight of the wild-type (n=5) (28.17 ± 0.36 g) 
(mean ± SE g) and ob/ob (n= 5) (44.98 ± 1.46 g) animals on day 0 pre-wounding (Fig. 5.6 
A). Both the wild-type control and ob/ob animals lost approximately 3 g of their body weight 
during the initial 3 days post wounding. This accounted for 4-6% of total body weight in the 
ob/ob (chronic wound) and 12% in the wild-type (acute wound) groups. The acutely 
wounded animals (wild-type) were unable to recover their weight 7 days post wounding 
(25.19 ± 0.99 g) (p<0.05) compared to day 0 (28.17 ± 0.36 g). Whereas, the chronically 
wounded animals (ob/ob) were able to regain the lost body weight with no difference 
detected between day 0 (44.96 ± 1.46 g) and day 7 (45.62 ± 0.99 g) (Fig. 5.6 A). Both groups 
had a 100% survival rate over the 7 days post wounding (Fig. 5.6 B1-2).  
The wounding procedure affected the appearance of both groups similarly with a score of 2 
(rough coat, slight discharges/lesions) throughout the 7 days (Fig. 5.6 C1). A similar change 
in behaviour was also evident in both groups with a peak score of 1.5 (less attentive and 
interactive) within the first 24h post wounding and then returning to normal from day 2 








Figure 5.6. Comparison of animal wellnes in mice with acute (wild-type C57BL6/J) (n=5) and chronic 
wounds (B6.cg-lepob/J, ob/ob) (n=5) over a period of 7 days. A) Animal weight (g) of control (n=5) and 
obese (n=5) obtained on day 0 pre-wounding and day 2 and 7 post wounding and treatment. B) Kaplan-meier 
survival curve (%) of animals with B.1) Acute and B.2) Chronic wounds over 7 days post wounding. C) 
Wellness score in C.1) Acute and C.2) Chronic wounded animals were calculated by measuring appearance 
and behaviour. The dotted line indicates the appearance score which was assigned as follows: 1 – Well 
groomed, no discharges/ lesions and normal breathing/ posture; 2 – rough coat, slight discharges/lesions and 
abnormal breathing and 3 – very rough coat, noticeable discharges/ lesions and definite difficulty breathing. 
The solid line indicates the behaviour score which was assigned as follows: 1 – attentive, inquisitive, interactive 
and normal walk/pace; 2 – not very interactive, less attentive, less active and abnormal walk/pace and 3 – not 
active, unresponsive. Statistical analysis: Paired two-tailed T test. *p<0.05 indicates significant differences 
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5.2.2 Macroscopic wound closure is impaired in the new chronic wound model compared 
to acutely wounded animals 
The wounding procedure was performed consistently in both the acute and chronically 
wounded animals with no difference detected in macroscopic wound size between groups 
on day 0 immediately post wounding (Fig.  5.7 A). On day 7 post wounding, healing was 
evident in the acute group with wound closure and re-epithelialization visible, whereas no 
macroscopic signs of healing was evident within the chronic group (Fig. 5.7 B). 
Quantification of the percentage wound closure over the period of 7 days indicated a 
significant group effect (p<0.05) with 73.54 ± 3.08% (mean ± SE) wound closure in the acute 





Figure 5.7. Macroscopic wound closure in acute versus chronic wounds. A) Wound area (mm2) on day 
0 immediately post wounding. B) Representative images of acute and chronic wounds on day 0 and day 7 
post wounding of wild-type C57BL6/J mice treated with saline (Acute wound) and B6.cg-lepob/J (ob/ob), 
treated with NEP high (chronic wound). C) Percentage wound closure between day 0 and day 7 for both acute 
and chronic wounds were calculated using Image J software. Statistical analysis: Paired two-tailed T test. 






























5.2.3 Histological scoring index: microscopic wound healing 
5.2.3.1 Re-epithelialization is not evident in the chronic wounds  
In the wound edges, the epithelial layer was thicker in the ob/ob animals (chronic wounds) 
(92 ± 7 µm) (mean ± SE µm) than in the wild type animals (acute wounds) (65 ± 7 µm) (Fig. 
5.8-5.9). No signs of re-epithelization were however evident in the wound area of the chronic 
wounds (ob/ob animals) on day 7 post wounding, whereas newly formed epithelial were 
clearly visible in the acute wounds (wild type animals) at the same time point (Fig. 5.8-5.9). 
The newly formed epithelial layer in the wounded area of the acute wounds were furthermore 
thicker (89 ± 14 µm) than in the acute wound edges (65 ± 7 µm). Representative images 
illustrating re-epithelialization are shown in Figure 5.9.  
 
Figure 5.8. Epithelial thickness (µm). Epithelial thickness (µm) on day 7 post wounding of wild-type 
C57BL6/J mice treated with saline (Acute wound) and B6.cg-lepob/J (ob/ob), treated with high NEP (chronic 
wound) calculated using Image J software Statistical analysis: Paired two-tailed T test. *p<0.05 indicates 
significant differences between groups at the same time point. Statistical analysis for epithelial thickness in the 
































Figure 5.9. H&E stains of acute versus chronic day 7 wounds. Histological cross section of day 7 post 
wounding of A) type C57BL6/J mice treated with saline (Acute wound) and B) magnification of wound area 
(Black outlined box) showing granulation tissue formation epithelial thickness and cell nuclei within granulation 
tissue. C) B6.cg-lep ob/J (ob/ob), treated with high NEP (chronic wound) and D) magnification of wound edge 
(Black outlined box in image B) of chronic wound indicating wound edge and epithelium. Images (tile scan) 
were acquired at 10x magnification. 
 
5.2.3.2 The formation of granulation tissue is not evident in the chronic wounds 
No signs of granulation tissue was evident in the wound area of the chronic wounds (ob/ob 
animals) on day 7 post wounding, whereas newly formed granulation tissue was clearly 
noticeable in the acute wounds (wild type animals) (923.99 ± 131.71 µm) at the same time 
point (Fig. 5.9-5.10). Representative images showing granulation tissue formation are 





Figure 5.10. Granulation tissue (µm). Granulation tissue thickness (µm) on day 7 post wounding of wild-type 
C57BL6/J mice treated with saline (Acute wound) and B6.cg-lepob/J (ob/ob), treated with high NEP (chronic 
wound) calculated using Image J software. Statistical analysis: was not done because all values for chronic 
were 0.  
 
5.2.3.3 Cellularity within granulation tissue  
Cellularity within the granulation tissue was measured on day 7 post wounding by assessing 
the nuclear content (% of granulation tissue) within the acute vs chronic wounded areas. 
The chronic wounds had no evidence of granulation tissue formation and cellularity and 
could therefore not be assessed, whereas as 11.39 ±1.07% of the granulation tissue within 
acute wounds showed presence of nuclei at the same time point (Fig 5.11). Representative 
images indicating cellularity within the granulation tissue are shown in Figure 5.9.  
Figure 5.11. Cellularity in granulation tissue. Cellularity (percentage area) within granulation tissue on day 
7 post wounding of wild-type C57BL6/J mice treated with saline (Acute wound) and B6.cg-lepob/J (ob/ob), 
treated with high NEP (chronic wound) calculated using Image J software. Statistical analysis: was not done 


























































5.2.3.4 Blood vessels within granulation tissue of acute day 7 wounds 
Angiogenesis was measured by quantifying the number of blood vessels within the 
granulation tissue 7 days post wounding in acute and chronic wounds. The chronic wounds 
had no granulation tissue formation within the wound area hence no blood vessels whereas 
acute wounds had 43 ±13.42 blood vessels at the same time point within the wound area 
(Fig 5.12). Representative images showing angiogenesis within granulation tissue are 
shown in Figure 5.13.  
Figure 5.12. Number of Blood vessels in granulation tissue. Number of blood vessels within granulation 
tissue on day 7 post wounding of wild-type C57BL6/J mice treated with saline (Acute wound) and B6.cg-lepob/J 
(ob/ob), treated with high NEP (chronic wound) calculated using Image J software. Statistical analysis: was 

























Figure 5.13. Acute versus chronic day 7 wound Masson trichrome stains. Histological cross section on 
day 7 post wounding of A) type C57BL6/J mice treated with saline (Acute wound) and B) magnification of 
wound area (Black outlined box) indicating granulation tissue and epithelium. C) B6.cg-lep ob/J (ob/ob), treated 
with high NEP (chronic wound) and D) magnification of wound edge (Black outlined box in image B) of chronic 
wound indicating wound edge. Images (tile scan) were acquired at 10x magnification. 
 
5.2.3.5 Histological scoring parameters 
The overall histology index was used to give an indication of healing dynamics within the 
acute and chronic wounds on day 7 post wounding. Acute wounds (1.92 ± 0.64) had a 1.9 
fold higher histology score compared to the chronic wounds (1 ± 0) at the same time point 






Figure 5.14: Histology index of acute and chronic day 7 wounds. Histology score was assigned to acute 
and chronic day 7 wounds based on epithelial thickness, granulation tissue formation, cellularity and 
angiogenesis. Histological scoring was assigned as follows: ± 1 for little epidermal and dermal organization 
(epithelial thickness < 30µm in wound area), few capillary vessels (<10), many infiltrated cells (<10%) and no 
granulation tissue formation, ±2 for moderate epidermal and dermal organization (epithelial thickness < 100µm 
in wound area), newly formed capillary vessels (>10%) in the entire wound area, granulation tissue (>100µm) 
and ±3 for complete remodelling of the epidermis and dermis, well-formed capillary vessels. Statistics: All 
scores for chronic were 1. Paired two-tailed T test. *p<0.05 indicates significant differences between groups 
at the same time point. 
 
5.2.4 MMP-9 expression is higher in Chronic wounds compared to acute wounds 
Matrix metalloprotease-9 expression within the wounded area was determined during the 
first seven days post wounding (i.e. on day 0, 2 and 7) within acute and chronic wounds. 
The chronic wound group showed no significant change between day 0 (4.79 ±2.8) (mean 
fold change ± standard error of the mean), day 2 (5.06±4.22), and day 7 (2.82 ±0.87) (Fig. 
5.15). In the acute wound group, there was no significant differences between day 0 (1 ± 
0.3), day 2 (0.65 ± 0.05) and day 7 (1.04 ± 0.29) (Fig. 5.15). Although there was no significant 
difference within the groups there were significant differences in MMP-9 expression between 
the acute and chronic wound groups on all 3 days (day 0, 2 and 7 post wounding). The 
chronic wound consistently produced significantly more MMP-9 compared to the acute 

























Figure 5.15. MMP-9 expression in acute versus chronic wounds over 7 days, post wounding. Wound 
tissue was collected from wild-type C57BL6/J mice treated with saline (Acute wound) and B6.cg-lepob/J 
(ob/ob), treated with high NEP concentration (chronic wound) (n=3). Total protein extracted (0.25mg/µL) from 
these samples to determine MMP-9 expression levels. MMP-9 measurement is expressed in x fold change to 
Acute day 0 wound reference sample (Absorbance at 450nm). Statistical analysis: Repeated measures 
ANOVA with Dunnet’s multiple comparison test. *p<0.05 indicates significant differences between groups at 
the same time point. Values are presented as absorbance read (ELISA assay) (mean±SE).  
 
 
5.2.5 The protein profile varies between acute and chronic wounds in the early stages of 
healing 
Initially 663 proteins were detected in the acute and chronic day 2 wounds. Figure 5.16 
shows the raw data of the overall protein profile of all samples (acute and chronic). From 
these 663 proteins, 80 showed to have more than 1.5 fold change and 17 proteins from the 
80 were observed to be significantly different between the acute and chronic wound groups 
at the same time point. Figure 5.17 shows the 17 proteins observed to be significantly 






































Figure 5.16. Raw mass spectrometry data of the 663 identified proteins. Protein profile of tagged proteins 
detect in both wild-type C57BL6/J mice treated with saline (Acute wound) and B6.cg-lepob/J (ob/ob), treated 
with high NEP (chronic wound). Relative absorbance was measured over 2 h using the mass spectrometer. 
 
 
Figure 5.17. Protein observed to be significant between acute and chronic wounds. Proteomic analysis 
of type C57BL6/J mice treated with saline (Acute wound) and B6.cg-lep ob/J (ob/ob), treated with high NEP 
(chronic wound) observed significant differences in the expression of 17 proteins between the 2 groups. 






















Acute vs. Chronic:  *p<0.05 for all proteins 
RT: 0.00 - 130.01































































Chapter 6 : Discussion   
During normal wound healing there are four distinct overlapping phases (haemostasis, 
inflammation, proliferation and remodelling), however in non-healing diabetic wounds the 
progression from inflammation to proliferation and remodelling does not occur (Landén et 
al., 2016, Zhao et al., 2016). The inability of these wounds to advance through the wound 
healing sequence is not yet fully understood. One of the leading causes of death in diabetic 
patients are complications arising from these nonhealing foot ulcerations. The complex 
nature of these non-healing diabetic wounds has led to the failure of many therapeutic 
strategies in clinical settings, despite that they were successful in substandard animal 
models. Therefore, a need for an animal model that is able to reflect the features and 
complications of a human chronic wound environment will greatly inform us on complications 
that occur during the early stages of healing which could inform us on potential therapies for 
treatment of impaired healing in future. This study successfully demonstrated the 
development a non-healing diabetic wound in ob/ob mice that more closely mimics what is 
seen in patients’ wounds. In particular, this study showed administration of a high NEP 
concentration (1.02 mg/µL) to the margins of full-thickness excisional wounds on the dorsal 
surface of B6.Cg-Lepob/J (ob/ob) resulted in a) a lower initial inflammatory cytokine 
response in day 2 wound fluid, b) altered MMP-9, that remained elevated 2 and 7 days after 
wounding, compared to saline control, c) delayed wound closure and d) change in the levels 
of 17 proteins identified using mass spectrometry which are related to inflammation, 
proliferation, protease activity, remodelling, ribosomal function, cytoskeleton, neurofilament 
network, cell cycle processes and cell adhesion. 
The neuropeptide substance P plays an important role in the progression of the wound 
healing process specifically in a) the release of pro-inflammatory cytokines, b) as a 
chemoattractant for neutrophils, lymphocytes, monocytes and fibroblasts, c) the promotion 
of vasodilation and cell adhesion between leukocytes and endothelial cells and d) the 
initiation of DNA synthesis and proliferation of keratinocytes, fibroblasts and endothelial cells 
(Pradhan et al., 2011, Pradhan et al., 2009, Delgado et al., 2003, Antezana et al., 2002). 
Substance P expression is however regulated through enzymatic degradation by NEP. The 
insufficient production of this neuropeptide and the over expression of NEP has been shown 
to be one of the contributing factors in the delayed healing process in non-healing diabetic 
foot ulcers (Antezana et al., 2002, Spenny et al., 2002, Leal et al., 2015).  
Studies have demonstrated NEP enzyme activity of 20.6 ±4.5 pmol/hour/μg in diabetic 




ulcers in patients which is significantly higher than the 3.65 pmol/hr/μg activity in nondiabetic 
patients (Spenny et al., 2002, Antezana et al., 2002). We hypothesized that administration 
of NEP to the margins of full-thickness excisional wounds, induced in pre-diabetic mice 
B6.Cg-Lepob/J (ob/ob) would impair healing to an extent that a chronic wound develops 
which resembles the phenotype of diabetic ulcers in the clinical setting. In this study a dose 
response of three concentrations of NEP were used. The first low NEP concentration (0.33 
mg/µL -50 pmol/hour/ug) was based on the NEP activity in ulcer margins of diabetic patients 
mentioned previously, however these mice have a higher metabolic turnover compared to 
humans (Kleiber, 1975) and hence higher concentrations were used as dose treatments – 
medium NEP (0.68 mg/µL-100 pmol/hour/ug) and high NEP (1.02 mg/µL-150 pmol/hour/ug). 
This study demonstrated a diabetic wound model in pre-diabetic mice B6.Cg-Lepob/J (ob/ob) 
that resembles the patient diabetic ulcer using the high NEP treatment. Although there were 
no significant differences in NEP activity (day 2) between the treatment groups, the high 
NEP treatment produced consistently high MMP-9 expression (day 2 and day 7 post 
wounding), significantly lower substance P within wound area compared to NEP low 
treatment, a low chronic pro-inflammatory profile within wound fluid (day 2), delayed wound 
closure (day 7) with no formation of granulation tissue, re-epithelization and angiogenesis 
within the wound area of the chronic wound (day 7) and significant differences in the 
expression of proteins between chronic and acute day 2 wounds that have not been 
previously described to be directly implicated in wound healing but have downstream 
interactions that could possibly play a role in healing.  
During the optimization of the wounding procedure in phase I, an 83% survival rate was 
observed in the B6.Cg-Lepob/J (ob/ob). This is thought to be because of the adverse effects 
that the anaesthesia had on the mice upon prolonged exposure resulting in respiratory and 
heart failure (Gargiulo et al., 2012). In order to overcome this, exposure was decreased to 
≤ 10 minutes and the mice were shaved the day before wounding and not on the day of. 
A significant effect of time was observed in NEP activity of all four treatment groups (Saline, 
low NEP, medium NEP and high NEP) with a higher activity on day 0 compared to day 2. 
The presence of NEP within the wound bed was first detected 6 hours post wounding 
(Olerud et al., 1999), which could mean that peak increase in NEP might have been missed 
between the day 0 and day 2 time points. This diminished NEP activity could possibly be 
due to interactions with its substrate, substance P, resulting in decreased activity over time. 
The immunohistochemistry results of substance P staining showed greater expression on 




thereby further reaffirming substance P’s role in wounding healing.  The decrease in NEP 
activity at the day 2 time point could be the reason for the increase in substance P 
expression at the same time point for all four treatment groups. In order to overcome the 
limitation of decreased NEP activity over time, an investigation into increasing the number 
and frequency of NEP treatments should be conducted.  
During normal wound healing, MMP-9 degrades matrix proteins and growth factors, and as 
the wound progresses through the healing cascade its expression decreases. Previous 
studies have shown in chronic wounds MMP-9 has increased activity hindering the re-
epithelialization process and keratinocyte migration and attachment (Liu et al., 2009, 
Lobmann et al., 2002, Reiss et al., 2010). The high NEP treatment produced significantly 
greater MMP-9 compared to saline treatment group on day 2, which is consistent with 
increased MMP-9 expression in chronic wounds.  
The high concentration of NEP induced an overall decrease in levels of pro-inflammatory 
cytokine, chemokine and anti-inflammatory cytokine profile within the day 2 wound fluid 
compared to the saline treatment which indicates an initial delay in the inflammatory 
response. This delayed inflammatory response indicates that these wounds have been 
delayed in the onset of healing.  
The second phase of this study investigated and compared the wound healing dynamics 
and differences in the protein profile of the high NEP dosage in the creation of a chronic 
non-healing wound (in B6.Cg-Lepob/J ob/ob mice) to an acute wound (in wild-type C57BL6/J 
mice) during the early stages of wound healing. Mice in the chronic wound (B6.Cg-Lepob/J 
ob/ob) group had a significantly higher weight compared to the acute wounded group (wild-
type C57BL6/J) .  
Impaired wound healing in T2DM due to the hyperglycaemic environment results in 
decreased cellular proliferation, collagen synthesis and angiogenesis leading to delayed 
healing (Okonkwo and DiPietro, 2017). The chronic wounded group had significantly 
decreased percentage wound closure compared to the acute wounded group on day 7. The 
acute wounds on day 7 had almost completely re-epithelialized were as the chronic wounds 
displayed open wounds indicating delayed healing. These results were further reaffirmed by 
comparing the histological parameters of the acute and chronic wounds. The acute wounds 
had thicker epithelium, greater granulation tissue formation within the wound area compared 
to the chronic wound and a higher percentage cellularity (infiltrating cell) and number of 
blood vessels (angiogenesis) within the granulation tissue indicating that healing is in fact 




epithelium formation within the wound area and therefore no infiltrating cells and 
angiogenesis occurring. This lack of granulation tissue formation is consistent with what is 
observed in chronic wounds in diabetic patients (Berlanga-Acosta et al., 2013). The MMP-9 
expression in the chronic wounds at all 3 time points (day 0, 2 and 7) was found to be 
significantly greater than the acute wound. These observations taken together indicate that 
wounding healing in the chronic group has been successfully delayed by the administration 
of the high NEP treatment thereby resembling phenotypes observed in patient diabetic 
ulcerations.  
Out of the 663 proteins detected in the proteomic analysis of acute and chronic day 2 
wounds, there were 80 proteins of interest (Table 6.1). Of the 80 proteins only 17 proteins 
were deemed significantly different between the acute and chronic wound groups. From 
these 17 proteins Nidogen-1 and Alpha-1-acid glycoprotein 1 were shown to be the only 
known proteins to be directly involved in the wound healing process, specifically in the 
inflammation (Alpha-1-acid glycoprotein 1), proliferation and remodeling (Nidogen-1) 
stages.  
Alpha-1-acid glycoprotein 1 is an acute phase protein whose concentration increases in 
response to injury and inflammation and is known to modulate inflammation during the 
healing process (Fournier et al., 2000, van Dijk et al., 1991). Nidogen-1 is essential for the 
epidermal basement membrane formation and interacts with laminin and collagen IV to 
achieve this (Baranowsky et al., 2010). Nidogen-1 has also been shown to have interactions 
with MMPs (specifically MMP-3 and MMP-7). The remaining proteins have not been 
previously described directly in relation to wound healing: a) Stafin-1 and Stafin-3 have 
interactions with each other and function as intracellular thiol proteinase inhibitors (Bilodeau 
et al., 2009), b) Rpl3, Rpn1, Snrnp70, Rpl7a, Rps19, and Rpl22 are ribosomal proteins and 
interact with various other ribosomal subunits/proteins (Table 6.1), c) Microtubule-
associated protein 1B is a component of the neural cytoskeleton (Lu et al., 2004), d) Fatty 
acid-binding protein facilitates transport of fatty acid within the cytosol and between the 
cytosol and nucleus (Kaczocha et al., 2012), e) Band 4.1-like protein 2 could possibly be 
involved in anaphase of the cell cycle, f) Translationally controlled tumor protein could 
possibly be involved in cell growth, acute allergic response, and apoptosis (Fiucci et al., 
2003), g) Desmoglein-1-alpha forms a part of desmosomes located in the upper epidermis 
and mediates cell to cell adhesions (Kljuic and Christiano, 2003), h) Caveolae-associated 




i) Gamma-synuclein plays a role in neurofilament network integrity (Buchman et al., 1998) 
and could regulate the keratin network in skin by similarity.  
Although these proteins have no known function in wound healing some show shared 
common interactions and sometimes interact with each other. We were unable to find 
literature that define the role of ribosomal proteins that were significantly different between 
the groups in wound healing, this hence warrants further investigation. Stefin-1 and Stefin-
3  interact with each other and could potentially play a regulator role in antigen presentation 
(Bilodeau et al., 2009). They also interact commonly with Csta1, Gm5416, BC117090, 
BC100530 which are Cystatin type proteins that possibly function as endopeptidase 
inhibitors. Microtubule-associated protein 1B interacts with Gsk3b (Glycogen synthase 
kinase-3 beta – negative regulator of glucose homeostasis) (Tanabe et al., 2008) and 
Pafah1b1 (Platelet-activating factor acetylhydrolase IB subunit alpha)  could possibly play a 
role in migration of fibroblasts during wound healing. Band 4.1-like protein 2 interacts with 
Epb4.13 (Band 4.1-like protein 3 – promotes apoptosis and inhibits cell proliferation). 
Caveolae-associated protein 1 interacts with Cav-1 (Caveolin-1 – T-cell activation and 
proliferation) (Ohnuma et al., 2007). Gamma-synuclein interacts with Mmrn2 (Multimerin-2- 
negative regulator of angiogenesis and inhibitor of epithelial cell mobility) (Lorenzon et al., 
2012). These proteins although not directly implicated in wound healing, have interactions 
with proteins that do and are overexpressed in the chronic compared to the acute wounds. 
There are two possible explanations for the overexpression of these proteins in chronic 
wounds – 1) a positive feedback loop or 2) delayed onset healing. The positive feedback 
loop refers to a lack of the usual negative feedback control resulting in accumulation of 
proteins in the chronic wounds. In the acute wounded groups the significantly higher proteins 
should have already been downregulated but in the chronic wounded group they remained 
high with delayed onset healing. 
This information suggests that there are dysregulations in overexpression and further 
research to investigate more details of the dysregulation and where exactly it originates 
needs to be conducted. The question can be asked: Is it because of a positive feedback 
loop or a delay in the onset of healing? A greater number of time points with higher animal 




Table 6.1: Protein expression in acute versus chronic wounds. 
Accession Number Identifier  Known function in wound healing  Novel Identified  Interactions Acute Chronic 
DDX5_MOUSE 
Probable ATP-dependent 
RNA helicase DDX5 
(Ddx5) 
-  
Dhx5, Cdc5l, Hnrnph1. Dhx9, 
Hnrnpk, Drosha, Hnrnpa2b1, 
Hnrnph2, Srsf6 and Hnrnpa1. 
0,70 2,00 
NID1_MOUSE Nidogen-1 (Nid1) 
Proliferation and 
remodelling (Baranowsky et 
al., 2010). 
- 
Lamc1, Lamb1, lama2, Lama1, 
Lama4, Lama5, MMP3, MMP7, 
Lamb2 and Lamc 3. 
0,83 1,60* 
NUDC_MOUSE Nuclear migration protein (NudC) - 
Roles in neurogenesis and neuronal migration 
(Keays, 2007, Sasaki et al., 2005). 
Pafah1b1, Dync1h1, Plk1, 
Ndel1, Nde1, Dync1i1, Clip1, 
Zw10, Dynll2 and Nuf2.  
1,07 1,77 
CYT3_MOUSE Stefin-3 (Stfa3) - Intracellular thiol proteinase inhibitor(Bilodeau et al., 2009). 
mCG_130165, Stfa2l1, 
BC100530, Stfa1, BC117090, 
Gm5416, Gm5483, Rptn, Sprr3 
and Csta1. 
1,20 3,77* 
RL3_MOUSE 60S ribosomal protein L3 (Rpl3) - 
L3 protein is a component of the large subunit of 
cytoplasmic ribosomes. 
Rpl8, Rps8, Rps3, Rps5, 
Rps19, Rpl10a, Rps11, Rpl23, 
Rps6 and Rps14. 
0,77 1,73* 
sp|P37889| Fibulin-2 (Fbln2) 
Proliferation and 
remodelling (Longmate et 
al., 2014, Lee et al., 2004). 
- 
Mfap5, Mfap2, Vtn, Mfap4, 






interacting 1 (Pin1) 
Angiogenesis and 
proliferation (Atabay et al., 
2015, Su et al., 2018). 
- 
Trp53, Hipk2, Irf3, Pip4k2a, 
Pip4k2b, Pip4k2c, Trp53inp1, 
Fkbp1a and Fkbp1b. 
1,17 1,77 
sp|Q9DB34| Charged multivesicular body protein 2a (Chmp2a) 
Remodelling (Olmos and 
Carlton, 2016). 
Formation and sorting of endosomal cargo 
proteins into multivesicular bodies through 
endosomal sorting required for transport 
complex III (ESCRT-III).  
Vps4b, Chmp4b, Chmp5, 
Chmp4c, Vps4a, Vta1, Chmp6, 
Chmp7, Vps36 and Chmp3. 
0,87 2,07 
CALU_MOUSE Calumenin (Calu)  Calcium-binding protein localized in the endoplasmic reticulum (Yabe et al., 1997). 
P4hb, Hsp90b1, Pcsk9, Pdia6, 
Alb, Nucb1, Fga, Fn1, Il6, Fstl1. 1,00 2,47 
STRN_MOUSE Striatin (Strn)  
Protein regulator of vesicular trafficking in 
neurons that also binds caveolin-1 and Ca2+-
calmodulin(Garza et al., 2015). 
Mob4, Strip1, Strip2, Mst4, 
Cttnbp2nl, Stk24, Ppp2r1a, 
Stk25, Slmap and Cttnbp2. 
1,50 1,93 
sp|Q8R326| Paraspeckle component 1 (Pspc1) 
 
Control of gene expression during many cellular 
processes including differentiation, viral infection, 
and stress responses (Fox and Lamond, 2010). 
Sfpq, Nono, Rbm14, Tatdn1, 
Cdc5l, Ppp5c, Srsf1, Fus, 







subunit 1 (Rpn1) 
 Recognition of several ligands of the 
proteasome(Elsasser et al., 2002). 
Rpn2, Ddost, Stt3a, Stt3b, 
Dad1, Ostc, Sec61a1, Tusc3, 
Ost4 and Sec61g. 
1,20 2,47* 
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sp|Q91VJ2| Caveolae-associated protein 3 (rkcdbp) 
 
Caveolin-3 knockout mice showed increased 
adiposity and insulin resistance and instability of 
the insulin receptor in skeletal muscle (Capozza 
et al., 2005). 
Cav1, Sprtn, Nenf, Mthfd1, 




U1 small nuclear 
ribonucleoprotein 70 kDa 
(Snrnp70) 
 mRNA splicing factor and component of the 
spliceosomal U1 snRNP (Carlson et al., 2015). 
Snrpc, Snrpd3, Snrpd1, 
Snrpd2, Snrpd, Snrpe, Snrpf, 
Gm8186, Srsf1 and Snrpa. 
1,00 1,80* 
sp|P14873| Microtubule-associated protein 1B (Map1b) 
 Major component of the neuronal 
cytoskeleton(Bloom et al., 1985, Lu et al., 2004). 
Gan, Fmr1,Dig4, Gsk3b, 
Pafah1b1, Map1lc3a, Dag2, 
Cyfip1, Mapre3 and Map2. 
1,10 2,57* 
sp|Q60590| Alpha-1-acid glycoprotein 1 (Orm1) 
Inflammation (Van Dijk et 
al., 2013, Fournier et al., 
2000). 
 Ahsg, Hp, Ttr, Alb, Orm2, Fgb, 






DNA replication, recombination and repair by 
binding to single-stranded DNA (Ruhanen et al., 
2010). 
Peo1, Polg, Tfam, Polrmt, 
Mrps6, Nip7, Polg2, Ccdc58, 
Nhp2 and Dut. 
1,00 1,80 
RL7A_MOUSE Ribosomal protein L7A (Rpl7a) 
 Encodes 60S ribosomal protein L7a. 
Rpl8, Rpl19, Rpl7, Rpl26, 
Rpl37a, Rpl32, Rpl18, Rpl15, 
Rpl30 and Rpl23. 
1,23 1,50* 
sp|Q80WJ7| Protein LYRIC (Mtdh)  Activates the nuclear factor kappa-B (NF- kappa-B) transcription factor (Noch and Khalili, 2013). 
Snd1, Lpar6, Sgol1, Rasal2, 
Emp2, Zcrb1, Cyp24a1, 
Slc1a2, Tspyl5 and Mmp9. 
1,70 1,6 
PPIB_MOUSE Peptidyl-prolyl cis-trans isomerase B (Ppib) 
 
Catalyses the cis-trans isomerization of proline 
imidic peptide bonds in oligopeptides (Lang et 
al., 1987). 
Crtap, Lepre1, P4hb, Leprel1, 
Serpinh1, Pdia4, Leprel2, 
Col1a1, Col1a2 and Hspa5. 
0,80 2,63 
       
RS11_MOUSE Ribosomal protein S11 (Rps11) 
 Encodes 40S ribosomal protein S11. 
Rpl8, Rps14, Rps5, Rps15a, 
Rpl10a, Rps3a1 , Rps13, 
Rpl23, Rpl35a and Rps25. 
1,30 1,97 
LBR_MOUSE Lamin-B receptor (Lbr)  Integral membrane protein of the interphase nuclear envelope (Olins et al., 2010). 
Lmnb1, Lemd3, Cbx5, Emd, 
Cyp51, Sqle, Ahctf1, Sun2, 
Banf1 and Hsd17b7. 
1,33 2,10 
CYT1_MOUSE Stefin-1 (Stfa1)  Intracellular thiol proteinase inhibitor. 
BC100530, Staf2l1, Gm5483, 
Staf3, Gm5416, Bc117090, 
mCG_130165, Gm4758, Csta1 
and Gm5689. 
1,13 2,00* 
sp|Q05816| Fatty acid-binding protein, epidermal (Fabp5) 
 Apart of the fatty acid binding family and has a 
high specificity for fatty acids.  
Ppard, Rxra, Grn, Acly, Retn, 
Trtr, Abca13, Pygb, Nckap1l 
and Fuca1. 
1,27 2,47* 
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RS19_MOUSE 40S ribosomal protein S19 (Rps19) 
 Needed for pre-rRNA processing and maturation 
of 40S ribosomal subunits. 
Rpl8, Rpl10a, Rps11, Rps25, 
Rps24, Rpl3, Rpl23, Rps15a, 
Rpl5 and Rps14. 
1,13 1,61* 
sp|Q8CGN5| Perilipin-1 (Plin1)  Controls adipocyte lipid metabolism. 
Abhd5, Cav1, Cidec, Prkacb, 
Prkaca, Pnpla2, Lipe, Prkg1, 
Prkg2 and Adipoq. 
1,30 2,43 
HPT_MOUSE Haptoglobin (Hp) 
Haemostasis and 
Inflammation (Venteclef et 
al., 2011, MacKellar and 
Vigerust, 2016). 
Acts as an antioxidant, has antibacterial activity 
and plays a role in modulating many aspects of 
the acute phase response (Wassell, 2000). 
Cd163, Apoa1, Hba-a1, Orm1, 
Hbb-bs, Orm2, Ltf, Lrg1, Cyfip1 
and Fth1. 
1,07 2,20 
VIME_MOUSE Vimentin (Vim) 
Proliferation, differentiation 
and re-epithelization (Cheng 
et al., 2016, Walker et al., 
2018, LeBert et al., 2018, 
Cheng and Eriksson, 2017). 
 
Des, Tpm4, Casp3, Neb, 
Tpm2, Tpm1, Casp8, Tnnt3, 
Casp7 and Casp6. 
0,87 1,97 
sp|O70318| Band 4.1-like protein 2 (Epb4.1l2) 
 Involved in anaphase of cell cycle. 
Epb4.1l3, Cask, Nrxn3, Nrxn2, 
Nrxn1, Epb4.1l1, Epb4.1l5, 
Epb4.1, Nlgn2 and Nlgn1 
0,90 1,53* 
ZO1_MOUSE Tight junction protein ZO-1 (Tjp1) 
Angiogenesis (Shi et al., 
2018).  
 
Gja1, Ocln, Src, Mllt4, Casp3, 
Cldn2, Cldn5, Wwtr1, Vcl and 
Ctnna1. 
1,10 1,73 
K2C1_MOUSE Keratin, type II cytoskeletal 1 (Krt1) 
Inflammation and re-
epithelialization (Roth et al., 
2012, Tao et al., 2007, 
Nuutila et al., 2012, 
Kobielak and Boddupally, 
2014). 
 
Lor, Krt5, Krt19, Krt77, Krt2, 
Krt10, Tgm1, Ivl, Trp63 and 
Hrnr. 
1,10 2,00 
TCTP_MOUSE Translationally controlled tumor protein (Tpt1) 
 Implicated in cell growth, acute allergic 
response, and apoptosis (Fiucci et al., 2003). 
Eef1b2, Bcl2l1, Eef1g, Rpl8, 
Eef2, Rps25, Gnb2l1, Rps3, 
Rps14 and Rplp2. 
0,77 1,77* 
sp|Q61495| Desmoglein-1-alpha (Dsg1a) 
 Component of desmosomes present in the upper 
epidermis(Kljuic and Christiano, 2003). 
Pkp3, Pkp1, Dsp, Jup, Pkp2, 
Pkp4, Klk5, Dsc3, Dsc1 and 
Dsc2. 
1,47 2,03* 
RBM3_MOUSE RNA-binding protein 3 (Rbm3) 
 
Increases protein synthesis at both physiological 
and mild hypothermic temperatures (Dresios et 
al., 2005). 
Rpl4, Chtop, Pcbp1, Srsf1, 
Hnrnpk, Celf2, Srsf6, Snrpa, 
Celf1 and U2af2. 
1,43 1,87 
sp|O54724| Caveolae-associated protein 1 (Ptrf) 
 Caveolae formation and organization (Couet et 
al., 1997). 
Cav1, Ttf1, Polr1e, Polr1a, 
Nnmt, Polr1c, Taf1c, Tbp, 
Taf1b and Polr2l. 
0,87 1,80* 
NUCL_MOUSE Nucleolin (Ncl)  Nucleolar protein of growing eukaryotic cells(Ginisty et al., 1999). 
Fbl, Npm1, Wdr43, Nop58, 
Nop56, Wdr75, Nop14, Rps6, 
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sp|Q9QXS1| Plectin (Plec)  
Anchors intermediate filaments to junctional 
complexes, the nuclear envelope and 
cytoplasmic(Wiche and Winter, 2011). 
Itgb4, Col17a1, Fau, Gm9843, 
Itga6, Gnb2l1, Rps19, Rps3a1, 
Rpl26 and Cd151. 
1,37 2,47 
COF1_MOUSE  Cofilin-1 (Cfl1)  
Regulates actin cytoskeleton dynamics and 
involved in cytokinesis and cell motility 
(Hotulainen et al., 2005). 
Limk1, Actb, Limk2, Ssh1, 
Actg1, Ssh2, Wdr1, Ssh3, Cttn 
and Rhoa. 
0,97 2,17 
SYUG_MOUSE Gamma-synuclein (Sncg)  Role in neurofilament network integrity (Buchman et al., 1998). 
Uba2, Pfdn2, Sync, Atoh7, 
Fam78b, Mettl14, Bub1b, 
Pou4f2, Mmrn2 and Kcns3. 
1,07 3,57* 
RL22_MOUSE Ribosomal protein L22 (Rpl22) 
 Encodes 60S ribosomal protein L22. 
Rps6, Rpl30, Rpl26, Rps14, 
Rps8, Rpl10a, Rps13, Rps25, 




containing protein D2 
(Efhd2) 
Inflammation(Kroczek et al., 
2010, Peled et al., 2018). 
 
Arpc2, Arpc4, Actr2, Arpc3, 
Mapt, Ttll3, Trim67, Hspb7, 
Trim80 and Fbxo42. 
0,73 1,87 
PYGM_MOUSE Glycogen phosphorylase, muscle form (Pygm) 
 Catalyzes the breakdown 
of glycogen to glucose-1-phosphate.  
Gbe1, Agl, Phkg1, Pgm5, 
Pgm2, Ugp2, Phka1, Phkb, 
Amy1 and Pgm3. 
1,73 0,83 
sp|Q8CI43| Myosin light chain 6B (Myl6b)  
 Regulatory light chain of myosin. Does not bind 
calcium. 
Tpm2, Myh11, Tpm1, Myl12b, 
Tpm4, Mylk, Myl7, Acta2, Tln1 
and Actg2. 
3,20 1,27 
sp|Q99PR8| Heat shock protein beta-2 (Hspb2) 
 May regulate the kinase DMPK. 
Mapk14, Akt1, Mapk11, 
Hspa1b, Hsp90aa1, Hsp90ab1, 
Mapk12, Mapkapk2, Mapk13 
and Trp53. 
3,10 1,17 
sp|Q3MI48| Junctional sarcoplasmic reticulum protein 1 (Jsrp1) 
 Involved in skeletal muscle excitation/contraction 
coupling (EC) (Yasuda et al., 2013). 
Cacna1s, Rwdd2b, Ubn2, Srl, 
Ryr1, Atp2a1, Sypl2, Stac3, 
Casq1 and Klrg2. 
2,87 0,77 
sp|Q99MS7| EH domain-binding protein 1-like protein 1 (Ehbp1l1) 
 
Coordinates Rab8 and Bin1, plays a role in 
vesicle trafficking and involved in apical-directed 
transport in polarized epithelial cells (Nakajo et 
al., 2016). 
Frmd8, Tigd3, Sssca1, Bin1, 
Cdc42ep2, Fam89b, Kcnk7, 
Map3k11 and Dpf2. 
1,67 1,20 
sp|Q91VX2| Ubiquitin-associated protein 2 (Ubap2) 
 Encoded by UBap2 gene. 
Zfr, Larp1b, Mrps36, Kcmf1, 
Phc3, Man1a2, Tbl1x, Cdyl, 
Pde4dip and mCG_125090. 
1,87 1,10 
OSTP_MOUSE Osteopontin (Spp1) 
Inflammation (Sodek et al., 
2000, Weber and Cantor, 
1996, Weber et al., 2012). 
 
Cd44, Timp1, Il6, Fn1, Alb, 
Dmp1, tgb1, Mepe, Mmp7 and 
Fgf23. 
3,33 1,27 
sp|P49813| Tropomodulin-1 (Tmod1)  Regulates filament length in skeletal muscle (Gokhin et al., 2015). 
Neb, Tpm1, Tpm2, Ttn, 
Mybpc3, Tpm4, Tnnt2, Tnni2, 
Tnnt3 and Actn3. 
5,30 1,50 
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TENN_MOUSE Tenascin-N (Tnn)  Involved in neurite outgrowth and cell migration in hippocampal explants(Neidhardt et al., 2003). 
Vcan, Bcan, Sdc4, Itga8, Itga9, 
Itgav, Tnr, Itgb6, Itgb1 and 
Itgb3. 
2,57 0,83 
TRDN_MOUSE Triadin (Trdn)  
Contributes to the regulation of lumenal Ca2+ 
release via the sarcoplasmic reticulum calcium 
release channels (Zhang et al., 1997). 
Ryr2, Ryr1, Asph, Casq2, 
Fkbp1b, Ryr3, Jph2, Jph1, 
Cacna1s and Casq1. 
6,43 1,10 
JPH2_MOUSE Junctophilin-2 (Jph2)  
Contributes to the formation of junctional 
membrane complexes (JMCs) which link the 
plasma membrane with the endoplasmic or 
sarcoplasmic reticulum in excitable cells(Beavers 
et al., 2014, Golini et al., 2011). Provides a 
structural foundation for functional cross-talk 
between the cell surface and intracellular 
calcium release channels (Landstrom et al., 
2014). 
Trdn, Casq2, Ryr1, Ryr3, 




       
JPH1_MOUSE Junctophilin-1 (Jph1)  
Contributes to the formation of junctional 
membrane complexes (JMCs) which link the 
plasma membrane with the endoplasmic or 
sarcoplasmic reticulum in excitable cells (Golini 
et al., 2011).Provides a structural foundation for 
functional cross-talk between the cell surface 
and intracellular calcium release channels 
(Landstrom et al., 2014). 
Ryr1, Ryr3, Casq2, Jph3, Trdn, 
Sypl2, Jph2, Mtm1, Zc3h12c 
and Myo3b. 
2,47 0,80 
sp|Q8BWB1| Synaptopodin 2-like protein (Synpo2l) 
 
Accelerate nucleation of actin filament formation 
and to induce actin bundling (Chalovich and 
Schroeter, 2010). 
Ankrd1, Myom2, Myoz1, 
Myoz2, Nrap, Cmya5, Smpx, 




associated protein 5 
(Cmya5) 
 Involved in compartmentalisation of protein 
kinase A (PKA). 
Ttn, Ldb3, Actn2, Ckmt2, 
Myom2, Dtnbp1, Obscn, 
Myoz2, Tcap and Smpx. 
1,73 0,97 
LDB3_MOUSE LIM domain-binding protein 3 (Ldb3) 
 
Role in the interaction between the 58 
muscular Z-line and α-actinin-2 (Yamashita et 
al., 2014). 
Actn2, Myoz2, Ttn, Myot, 
Csrp3, Myl1, Tcap, Mypn, 
Actn3 and Tnni3. 
2,03 0,97 
BIN1_MOUSE Myc box-dependent-interacting protein 1 (Bin1) 
 Regulation of synaptic vesicle endocytosis (Wu 
et al., 2009). 
Dnm2, Wasl, Picalm, Dnm1, 
Dnm3, Sh3gl2, Eps15, Amph, 




glutamic acid-rich protein 
(Sh3bgr) 
 Forms a part of the SH3BGR family. 
Psmg1, Wrb, Ripply3, Kcnj6, 
Hmgn1, Brwd1, Egfr, Bace2, 
Xkr6 and Emc3. 
3,13 0,70 








subunit alpha (Naca) 
 
Regulates the expression of genes involved in 
the development of myotubes (Berger et al., 
2012). 
Btf3, Btf3l4, Rpl7, Rpl19, 
Rpl32, Rpl4, Rps27a, Rps17, 
Rpl8 and Smyd1. 
2,43 0,93 
H10_MOUSE Histone H1.0 (H1f0)  Condensation of nucleosome chains into higher-order structures (Brown et al., 2006). 
H1fx, Asf1a, Trp53, Hmgb1, 
Cdk2, Dffb, Hmgb2, Hist1h1e, 
Hist1h1b and Hist1h1d. 
2,33 1,37 
sp|D3Z1D3| ENSMUSG00000071540  RIKEN cDNA 3425401B19 gene. 
Dyrk1a, Dyrk1b, Dcaf7, 
ENSMUSG00000066607, 
Ercc6, Suds3, Ercc8, Ghr, Fnta 
and Dalrd3. 
2,77 1,13 
TPM1_MOUSE  Tropomyosin alpha-1 chain (Tpm1) 
 
Regulates myosin-actin interactions during 
muscle contraction and stabilizing cytoskeleton 
actin filaments in non-muscle cells (Singer et al., 
2000). 
Actn2, Tnnt2, Tnni1, Myh6, 
Tnni3, Tnnt3, Myl2, Myl3 and 
Acta2. 
2,33 1,13 
sp|Q91YE8| Synaptopodin-2 (Synpo2)  Actin-binding and actin-bundling activity (Luo, 2004). 
Kiaa0922, Tigd4, Rnf150, 
Ociad2, Ddit4l, Arfip1, Bag3, 
Scgn, Lias and Etfdh. 
2,77 0,97 
sp|Q8CI51| PDZ and LIM domain protein 5 (Pdlim5) 
 Contributes to heart development by scaffolding 
PKC to the Z-disk region. 
Vcl, Rwdd2b, Prkce, Sorbs2, 
Cacna1b, Actn1, Id2, Tpm2, 
Tpm1 and Acta2. 
2,83 1,17 
sp|Q9QZ47| Troponin T (Tnnt3)  Contraction of striated skeletal muscles (Wei and Jin, 2016). 
Tnni2, Tnnc2, Myl1, Actn3, 
Tnni1, Tpm2, Mybpc2, Tpm1, 
Tnni3 and Actn2. 
2,87 1,13 
H2AZ_MOUSE Histone H2A.Z (H2afz)  
Role in transcription regulation, DNA repair, DNA 
replication and chromosomal stability (Farris et 
al., 2005). 
H3f3a, Hist2h3c2, Cdk1, 
Hist1h4j, H2afb2, Ruvbl1, Sirt1, 
Hist2h2ab, Kdm1a and Cenpa. 
5,93 2,00 
sp|K1C15_SHEEP| Keratin 15 (KRT15)  Expressed in basal keratinocytes (Waseem et al., 1999). 
APCDD1L, TELO2, CCDC101, 
SYNM, LGR6, LGR5, 
DNAJC15, LRIG1, KRT5, 
KRT77. 
1,77 3,13 
sp|Q923D2| Flavin reductase (NADPH) (Blvrb) 
 
Catalyzes the NADPH-dependent reduction of a 
variety of flavins via broad specificity 
oxidoreductase (Cunningham et al., 2000). 
Hmox2, Hmox1, Blvra, Acp5, 
Rfk, Acp2, Bscl2, Ugt1a7c, 
Ugt2b1 and Ugt1a6b. 
1,93 3,17 
NFH_MOUSE Neurofilament heavy polypeptide (Nefh) 
 Maintain neuronal calibre (Yuan et al., 2012). 
Mapk14, Cdk5, Mapk11, 
Mapk13, Mapk12, Prph, Mbp, 
Calca, Nefl and Rbfox3. 
2,03 2,47 
RS14_MOUSE Ribosomal protein S14 (Rps14) 
 Encode for the 40S ribosomal protein S14. 
Rpl8, Rps5, Rps3, Rps25, 
Rps11, Rps15a, Rpl23, Rpl3, 
Rpl7 and Rpl5. 
1,67 2,00 
sp|P70232| 
Neural cell adhesion 
molecule L1-like protein 
(Chl1) 
 
Increases neuronal migration toward 
extracellular matrix proteins through endocytosis 
and MAP kinase signalling (Thelen et al., 2002). 
Cntn6, Nrp1, Itgb1, Itga1, Itga2, 
Stip1, Ptpra, Dcx, St8sia3 and 
Gdnf. 
2,63 2,07 
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IGJ_MOUSE Immunoglobulin J chain (Igj) 
 Links two monomer units of either IgM or IgA 
(Randall et al., 1992). 
Fcamr, Ambp, Pigr, Ighv1-73, 
Cd79b, Cd79a, Iglc2, Piga, Syk 
and Pigm. 
2,47 1,43 
HORN_MOUSE Hornerin (Hrnr)  Apart of the epidermal cornified cell envelopes (Henry et al., 2011). 
Serpinb3b, Serpinb3c, Cap1, 
Dpp7, Ctsa, Padi2, Serpinb3a, 
Fabp5, Serpina3m and Ctsg. 
2,80 1,63 




SPINK1, SERPINA5, ALB, PTI, 
KRT1, KRT2 and AMBP. 
1,73 1,63 
NFM_MOUSE Neurofilament medium polypeptide (Nefm) 
 Involved in the maintenance of neuronal calibre 
(Yuan et al., 2012). 
Nefl, Prph, Mapk14, Mapk11, 
Mapk13, Mapk12, Nes, Vim, 
Des and Tubb3. 
1,87 2,40 
RL28_MOUSE Ribosomal protein L28 (Rpl28) 
 Encodes for the 60S ribosomal protein L28. 
Rpl19, Rpl18, Rpl8, Rpl26, 
Rpl34, Rpl10a, Rpl37a, Rpl36a, 
Rpl13 and Rpl5. 
1,80 2,40 
sp|A2AMM0| Caveolae-associated protein 4 (Murc) 
 Controls the morphology of formed caveolae in 
cardiomyocytes (Ogata et al., 2008). 
Cav3, Trim54, Dact1, Mybph, 
Cav1, Sestd1, Cav2, Lrrc17, 
Tnnc2 and Csrp3. 
1,80 1,67 
H15_MOUSE Histone H1.5 (Hist1h1b)  Regulates individual gene transcription. 
Ubn1, Asf1a, Hist1h1a, Hmgb2, 
H1f0, Hist1h1e, Hmgb1, 
Hist1h1d, Hira and Trp53. 
3,53 1,67 
RL14_MOUSE Ribosomal protein L14 (Rpl14) 
 Encode for the 60S ribosomal protein L14. 
Rps8, Rps11, Rpl35a, Rps3a1, 
Rpl8, Rpl26, Rps3, Rps13, 
Rps19 and Rps14. 
2,33 3,20 
ATR_MOUSE Serine/threonine-protein kinase ATR (Atr) 
 Regulates DNA damage response mechanism 
(Goodarzi et al., 2003). 
Chek1, Atrip, Topbp1, Rad17, 
Chek2, Blm, Mre11a, Wrn, 
Rad50 and Fancm. 
2,63 1,27 
sp|K1C9_HUMAN| Keratin, type I cytoskeletal 9 (KRT9) 
 Keratin filament assembly. 
KRT1, KRT7, KRT6B, KRT6A, 
KRT8, KRT4, KRT72, KRT5, 
KRT6C and KRT3.  
1,83 2,17 
sp|Q8VEE1| LIM and cysteine-rich domains protein 1 (Lmcd1) 
 Role in the development of cardiac hypertrophy 
(Bian et al., 2010). 
Gata6, Taf6l, Pcnx, Sgsm2, 
Lbh, Sbspon, Tsc22d3, 
Prpf38a, Ppp2r5e and Dlx2. 
2,23 1,27 
sp|K1C10_HUMAN| KRT10 Re-epithelialization (Nuutila et al., 2012). 
 
KRT1, KRT77, KRT5, KRT2, 
KRT16, PRSS1, KRT8, KRT7, 
KRT72 and KRT4. 
1,70 2,07 
H14_MOUSE  Histone H1.4 (Hist1h1e)  Regulates individual gene transcription. 
Asf1a, Hist1h1d, Hist1h1a, 
Ubn1, H1f0, Cbx3, Hist1h1b, 






Accession Number Identifier  Known function in wound healing  Novel Identified  Interactions Acute Chronic 
       
H11_MOUSE Histone H1.1 (Hist1h1a)  Regulates individual gene transcription. 
Asf1a, Hist1h1b, Hist1h1e, 
Hmgb2, Hist1h1d, Hmgb1, 
Ubn1, H1f0, Hist1h1c and 
Hmga2. 
3,53 2,03 
sp|K2C1_HUMAN| Keratin, type II cytoskeletal 1 (KRT1) 
 Regulates the activity of kinases (Chuang and 
Huang, 2007). 
KRT10, KRT5, KRT2, KRT77, 
KRT9, PRSS1, KRT15, KRT13 
and KRT17.  
3,13 1,83 
sp|Q69ZR2| E3 ubiquitin-protein ligase HECTD1 (Hectd1) 
 Transfers the ubiquitin to targeted substrates. 
Ubr4, Trip12, Ubr2, Ubr1, 
Ube2, Ube2z, Ube2a, Ube2o, 
Hectd3 and Ube2u. 
1,77 2,63 
       
Footnote:  The table above displays proteins detected in both wild-type C57BL6/J mice treated with saline (Acute wound) and B6.cg-lepob/J (ob/ob), treated with NEP 




Chapter 7 : Conclusion, Future Perspectives and Limitations 
Non-healing diabetic foot ulcers are characterised by the hindered progression from the 
inflammatory stage to the proliferative stage of healing resulting in a chronic inflammatory 
state (Landén et al., 2016, Zhao et al., 2016). The impairment in the progression of these 
wounds is not yet well understood. There are many animal models available that have 
contributed greatly to our understanding of wound healing, however none of these models 
are able to replicate the phenotype of human wound chronicity observed in non-healing 
diabetic foot ulcerations. Currently, many therapeutic approaches fail in clinical settings. A 
need for new models that are able to recapitulate/mimic the features of patient non-healing 
diabetic wounds will provide a greater understanding of dysfunctions occurring during the 
early phases of healing. This will greatly inform decisions on treatment strategies so that 
they can be clinically beneficial for patients. 
Given results showing elevated NEP activity in the ulcer margins of diabetic patient foot 
ulceration compared to non-diabetic patients (Antezana et al., 2002) this study investigated  
the use of NEP in an animal wound model using B6.Cg-Lepob/J (ob/ob) to create a wound 
that tries to resemble the phenotype of non-healing diabetic wounds in patients. In addition, 
this study compared the impaired healing dynamics of this newly developed chronic wound 
model to that of a standard acute wound (C57BL/6J).  
It was demonstrated that the administration of a high NEP concentration (1.02 mg/µL) in the 
ulcer margins of wounds created on the dorsal surface of B6.Cg-Lepob/J (ob/ob) resulted in 
similar features to that of patient diabetic wounds – delayed onset inflammation (day 2), high 
MMP-9 expression, delayed wound closure, hindered angiogenesis, re-epithelialization and 
granulation tissue formation. Specifically, when comparing the acute wounds to the chronic 
wounds, the chronic wounds displayed greater MMP-9 expression (day 0, 2 and 7), 
significantly lower wound contraction, no re-epithelialization, granulation tissue formation 
and angiogenesis occurring indicating that wound healing has been successfully hindered.  
Proteomic analysis of the acute and chronic wounds indicated significant differences in the 
expression of proteins (Stefin-1, Stefin-3, Microtubule- associated protein 1B, Band 4.1-like 
protein 2, Caveolae-associated protein 1 and Gamma-synuclein) between chronic and acute 
wounds that have not been previously described to be directly implicated in wound healing. 
These proteins’ functions were identified, and they could have downstream interactions that 
might play a role in healing. Two proteins known to be directly involved in wound healing 




also differed. The overexpression of these proteins in chronic wounds could be attributed to 
either a positive feedback loop (elevated protein levels but downstream functions are 
impaired) or delayed onset healing (proteins have already been downregulated in acute 
group but remain elevated in chronic groups thereby delaying the onset of healing). 
Research needs to still be conducted on where exactly the dysregulation originates from.  
Due to the small volume of wound fluid collected from each animal, wound fluid had to be 
pooled together for cytokine analysis limiting the establishment of variability in the cytokine 
levels amongst mice in each group, making statistical significance difficult to obtain. In future 
studies this will not change but this limitation can be overcome by increasing the number of 
animals per group so that at least 3 pooled samples are available for each treatment group. 
The chronic wounds were not directly compared to chronic patient wounds but rather 
literature was used as a guide to define characteristics of patient chronic wounds. The 
chronic wound induced in this study was monitored up to 7 days and not for a longer duration 
therefore it remains to be investigated to what extent does this method mimic a chronic 
wound with delayed healing or no healing.  
In conclusion, high NEP administration in the wound edges of obese pre-diabetic mice 
resulted in a chronic wound model that better mimics human diabetic chronic wounds than 
lower NEP concentrations or saline administration. High NEP administration resulted in 
significantly lower wound closure that could be explained by higher MMP-9, lower cytokine 
content in wound fluid and differences in several proteins identified by proteomic analysis, 
however further work needs to be conducted to investigate to what extent this method 
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Chapter 9 : Appendices 




Date: 30 – June – 2017 
PI Name: Van De Vyver, Mari M 
Protocol #: SU-ACUD17-00016 
Title: Development of a chronic wound model using B6.Cg-Lepob/J obese diabetic and C57BL/6J wild-
type control mice: Characterizing cellular changes that impair regenerative potential of wound-derived 
fibroblasts and endogenous mesenchymal stem cells. 
Dear Mari Van De Vyver, the Response to Modification, was reviewed on 23-June-2017 by the Research 
Ethics Committee: Animal Care and Use via committee review procedures and was approved. Please note 
that this clearance is only valid for a period of twelve months. Ethics clearance of protocols spanning 
more than one year must be renewed annually through submission of a progress report, up to a 
maximum of three years. 
Applicants are reminded that they are expected to comply with accepted standards for the use of 
animals in research and teaching as reflected in the South African National Standards 10386: 2008. The 
SANS 10386: 2008 document is available on the Division for Research Developments website 
www.sun.ac.za/research. 
As provided for in the Veterinary and Para-Veterinary Professions Act, 1982. It is the principal 
investigator's responsibility to ensure that all study participants are registered with or have been 
authorised by the South African Veterinary Council (SAVC) to perform the procedures on animals, or will 
be performing the procedures under the direct and continuous supervision of a SAVC-registered 
veterinary professional or SAVC-registered para-veterinary professional, who are acting within the 
scope of practice for their profession. 
Please remember to use your protocol number, SU-ACUD17-00016 on any documents or 
correspondence with the REC: ACU concerning your research protocol. Please note that the REC: ACU has 
the prerogative and authority to ask further questions, seek additional information, require further 
modifications or monitor the conduct of your research. Any event not consistent with routine expected 
outcomes that results in any unexpected animal welfare issue (death, disease, or prolonged distress) or 
human health risks (zoonotic disease or exposure, injuries) must be reported to the committee, by 
creating an Adverse Event submission within the system. 
We wish you the best as you conduct your research. If you have any questions or need further help, please 
contact the REC: ACU secretariat at wabeukes@sun.ac.za or 021 808 9003. 
 
Sincerely, REC: ACU Secretariat 








Date: 15 June 2018 
PI Name: Dr. 
Mari Van de 
Vyver Protocol 
#:3857 
Title: Development of a chronic wound model using B6.Cg-Lepob/J obese diabetic and C57BL/6J wild-type 
control mice: Characterizing cellular changes that impair regenerative potential of wound-derived 
fibroblasts and endogenous mesenchymal stem cells. 
 
Dear Mari Van de Vyver , 
 
The Development of a chronic wound model using B6.Cg-Lepob/J obese diabetic and C57BL/6J wild-type 
control mice: Characterizing cellular changes that impair regenerative potential of wound-derived 
fibroblasts and endogenous mesenchymal stem cells - amendment. , was reviewed on 13 June 2018 by 
the Research Ethics Committee: Animal Care and Use via committee review procedures and was 
approved. Please note that this clearance is only valid for a period of twelve months. Ethics clearance of 
protocols spanning more than one year must be renewed annually through submission of a progress 
report, up to a maximum of three years. 
New Co-workers: 
Kiara Boodhoo (MSc student) and Dr Dalene de Swardt (Postdoc) 
Applicants are reminded that they are expected to comply with accepted standards for the use of animals 
in research and teaching as reflected in the South African National Standards 10386: 2008. The SANS 
10386: 2008 document is available on the Division for Research Developments website 
www.sun.ac.za/research. 
As provided for in the Veterinary and Para-Veterinary Professions Act, 1982. It is the principal 
investigator's responsibility to ensure that all study participants are registered with or have been 
authorised by the South African Veterinary Council (SAVC) to perform the procedures on animals, or will 
be performing the procedures under the direct and continuous supervision of a SAVC-registered 
veterinary professional or SAVC-registered para-veterinary professional, who are acting within the scope 
of practice for their profession. 
Please remember to use your protocol number 3857 on any documents or correspondence with the REC: 
ACU concerning your research protocol. 
 
Please note that the REC: ACU has the prerogative and authority to ask further questions, seek additional 
information, require further modifications or monitor the conduct of your research. 
Any event not consistent with routine expected outcomes that results in any unexpected animal welfare 
issue (death, disease, or prolonged distress) or human health risks (zoonotic disease or exposure, injuries) 
must be reported to the committee, by creating an Adverse Event submission within the system. 
We wish you the best as you conduct your research. 
If you have any questions or need further help, please contact the REC: ACU Secretariat 
at wabeukes@sun.ac.za or 021 808 9003. Sincerely, 
Winston Beukes REC: ACU Secretariat 




Appendix B: Animal Wellness monitoring sheet 
FMHS Animal Research Facility Health and Welfare Monitoring Sheet 
 
  Monitoring must be performed twice a day if a cage is scored  
"2" Veterinary staff must be alerted if a cage is scored "3" 
Cage ID: Group description: 
 email: tel: 
Researcher: email: tel: 
Protocol #: 
Date Time Appearance Behaviour Cage Comments Initials 
       
       
       
       
       
       
       
   
: 
   
       
       
       
       
       
       
       
       
       
       
       
Appearance 1: well-groomed; bright facial expresion; no discharges; no lesions; normal posture/breathing 
 2: coat slightly rough; subtle discharges/lesions; dull facial expression; mild hunching; abnormal breathing 
 3: staring coat; obvious discharges/lesions; facial bulge/squinting; hunched posture; breathing difficulty 
Behaviour 1. Alert; curious; active; interactive with cage mates; normal gait 
 2: less active; isolated from cage mates; less responsive; abnormal gait 
 3: inactive; poorly responsive; 
















Appendix D: Abbreviations for Table 6.1 
A2m:   Alpha-2-macroglobulin-P 
Abca13:  ATP-binding cassette 
Abhd5:  1-acylglycerol-3-phosphate O-acyltransferase 
Acly:   ATP-citrate synthase 
Acp2:   Acid phosphatase 2 
Acp5:   Tartrate-resistant acid phosphatase type 5 
Acta2:  Actin, aortic smooth muscle 
Actb:   Actin, cytoplasmic 1 
Actg1:  Actin, cytoplasmic 2 
Actg2:  Actin, gamma-enteric smooth muscle 
Actn:   Alpha-actinin 
Actr:   Actin-related protein 
Adipoq:  Adiponectin 
AGE:   Advanced glycation end-products 
Agl:   Amylo-1,6-glucosidase 
Ahctf1:  Protein ELYS 
Ahsg:   Alpha-2-HS-glycoprotein 
Akt1:   RAC-alpha serine/threonine-protein kinase 
Alb:   Serum albumin 
Ambp:  Protein AMBP, Inter-alpha-trypsin inhibitor inhibits trypsin 
Amph:  Amphiphysin 
Amy:   Amylase 
Ankrd1:  Ankyrin repeat domain-containing protein 1 
APCDD1L:  Adenomatosis polyposis coli down-regulated 1-like 
Apoa1:  Apolipoprotein A-I 




Arpc:   Actin-related protein 2/3 complex subunit 
Asf1a:  Histone chaperone ASF1A 
Asph:   Aspartyl/asparaginyl beta-hydroxylase 
Atoh:   Protein atonal homolog 
Atp2a1:  Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 
Atrip:   ATR-interacting protein 
Bace2:  Beta-secretase 2 
Bag3:   BAG family molecular chaperone regulator 3 
Banf1:  Barrier-to-autointegration factor 
BC100530:  MCG130175, isoform CRA_b 
BC117090:  cDNA sequence BC1179090 
Bcan:   Brevican core protein 
Bcl2l1:  Bcl-2-like protein 1 
Bin1:   Myc box-dependent-interacting protein 1 
Blm:   Bloom syndrome protein homolog 
Blvra:  Biliverdin reductase A 
Brwd1:  Bromodomain and WD repeat-containing protein 1 
Bscl2:  Seipin 
Btf3:   Transcription factor BTF3 
Btf3l4:  Basic transcription factor 3-like 4 
Bub1b:  Mitotic checkpoint serine/threonine-protein kinase BUB1 beta 
C3:   Complement C3 
Cacna1b:  Voltage-dependent N-type calcium channel subunit alpha-1B 
Cacna1s:  Voltage-dependent L-type calcium channel subunit alpha-1S 
Calca:  Calcitonin 
Cap1:  Adenylyl cyclase-associated protein 1 




Casp:   Caspase 
Casq:   Calsequestrin  
Casq1:  Calsequestrin-1  
Cav:   Caveolin 
Cbx:   Chromobox protein homolog  
CCDC101:  Uncharacterized protein; Coiled-coil domain containing 101 
Ccdc58:  Coiled-coil domain containing 58  
Cd151:  CD151 antigen 
Cd163:  Scavenger receptor cysteine-rich type 1 protein M130 
Cd44:  CD44 antigen 
Cd79a:  B-cell antigen receptor complex-associated protein alpha chain 
Cd79b:  B-cell antigen receptor complex-associated protein beta chain 
Cdc42ep2:  Cdc42 effector protein 2 
Cdc5l:  Cell division cycle 5-like protein 
Cdh2:  Cadherin-2 
Cdk:   Cyclin-dependent kinase  
Cdyl:   Chromodomain Y-like protein 
Celf:   CUGBP Elav-like family member  
Cenpa:  Histone H3-like centromeric protein A 
Chek1:  Serine/threonine-protein kinase Chk1 
Chek2:  Serine/threonine-protein kinase Chk2 
Chmp4b:  Charged multivesicular body protein 4b. 
Chmp5:  Charged multivesicular body protein 5 
Chtop:  Chromatin target of PRMT1 protein 
Cidec:  Cell death activator CIDE-3 
Ciz1:   CDKN1A interacting zinc finger protein 1 




Cldn:   Claudin 
Clip1:   CAP-Gly domain-containing linker protein 1 
Cmya5:  Cardiomyopathy-associated protein 5 
Cntn6:  Contactin-6 
Col17a1:  Collagen alpha-1(XVII) chain 
Col1a1:  Collagen alpha-1(I) chain 
Col1a2:  Collagen alpha-2(I) chain 
Col6a1:  Collagen alpha-1(VI) chain 
Cpsf6:  Cleavage and polyadenylation specificity factor subunit 6 
Crtap:  Cartilage-associated protein 
Csrp3:  Cysteine and glycine-rich protein 3 
Csta1:  Cystatin-A 
Ctnna1:  Catenin alpha-1 
Ctsa:   Lysosomal protective protein 
Ctsg:   Cathepsin G 
Cttn:   Src substrate cortactin 
Cttnbp2:  Cortactin-binding protein 2 
Cttnbp2nl:  CTTNBP2 N-terminal-like protein 
Cyfip1: Cytoplasmic FMR1-interacting protein 1 
Cyp24a1:  1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial 
Cyp51:  Lanosterol 14-alpha demethylase 
Dact1:  Dapper homolog 1 
Dad1:  Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit  
Dag2:  Disks large homolog 2 
Dalrd3:  DALR anticodon-binding domain-containing protein 3 
Dcaf7:  DDB1- and CUL4-associated factor 7 




Ddit4l:  DNA damage-inducible transcript 4-like protein 
Ddost:  Dolichyl-diphosphooligosaccharide--protein glycosyltransferase  
Des:   Desmin 
Dffb:   DNA fragmentation factor subunit beta 
Dhx5:   Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 
Dhx9:   ATP-dependent RNA helicase A 
Dig4:   Disks large homolog 4 
Dlx2:   Homeobox protein DLX-2;     
Dmp1:  Dentin matrix acidic phosphoprotein 1 
DNAJC15:  DnaJ (Hsp40) homolog, subfamily C, member 15 
Dnm:   Dynamin 
Dpf2:   Zinc finger protein ubi-d4 
Dpp7:  Dipeptidyl peptidase 2 
Drosha:  Ribonuclease 3 
Dsc:   Desmocollin 
Dsg1a:  Desmoglein-1-alpha 
Dsp:   Desmoplakin 
Dtnbp1:  Dysbindin 
Dut:   Deoxyuridine triphosphatase, isoform CRA_b 
Dync1h1:  Cytoplasmic dynein 1 heavy chain 1 
Dync1i1: Cytoplasmic dynein 1 intermediate chain 1 
Dynll2:  Dynein light chain 2, cytoplasmic 
Dyrk1:  Dual specificity tyrosine-phosphorylation-regulated kinase 1 
E4f1:   Transcription factor E4F1 
Eef1:   Elongation factor 1 
Egfr:   Epidermal growth factor receptor  




Emc3:  ER membrane protein complex subunit 3 
Emd:   Emerin 
Emp2:  Epithelial membrane protein 2 
ENSBTAG00000011995:  Chymotrypsinogen A 
ENSBTAG00000024245:  Cationic trypsin Alpha-trypsin chain 1 Alpha-trypsin chain 2 
ENSBTAG00000026119:  Uncharacterized protein 
ENSMUSG00000066607:  UPF0583 protein C15orf59 homolog 
Epb4.1:  Protein 4.1 
Epb4.1l:  Band 4.1-like protein 
Epb4.1l2:  Band 4.1-like protein 2 
Epb4.1l3:  Band 4.1-like protein 3 
Eps15:  Epidermal growth factor receptor substrate 15 
Ercc:   Excision repair cross-complementing rodent repair deficiency 
Etfdh:   Electron transfer flavoprotein-ubiquinone oxidoreductase 
Fabp5:  Fatty acid-binding protein, epidermal 
Fam78b:  Protein FAM78B 
Fam89b:  Leucine repeat adapter protein 25 
Fancm:  Fanconi anemia group M protein homolog 
Fau:   Ubiquitin-like protein FUBI 
FblL:   rRNA 2’-O-methyltransferase fibrillarin 
Fbxo:   F-box only protein 
Fcamr:  High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor 
Fga:   Fibrinogen alpha chain 
Fgb:   Fibrinogen beta chain 
Fgf:   Fibroblast growth factor 
Fgg:   Fibrinogen gamma chain 




Fkbp1b:  Peptidyl-prolyl cis-trans isomerase FKBP1B 
Fmr1:   Synaptic functional regulator 
Fn1:   Fibrinogen alpha chain 
Fnta:   Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha 
Frmd8:  FERM domain containing 8 
Fstl1:   Follistatin-related protein 1 
Fth1:   Ferritin heavy chain 
Fuca1:  Tissue alpha-L-fucosidase 
Fus:   RNA-binding protein FUS  
Gan:   Gigaxonin 
Gata6:  Transcription factor GATA-6 
Gbe1:  1,4-alpha-glucan-branching enzyme 
Gdnf:   Glial cell line-derived neurotrophic factor 
Ghr:   Growth hormone receptor 
Gja1:   Gap junction alpha-1 protein 
Gm4758:  Predicted gene 4758 
Gm5416:  Predicted gene 5416 
Gm5483:  MCG130182, isoform CRA_a 
Gm5689:  Predicted gene 5689 
Gm8186:  Small nuclear ribonucleoprotein G 
Gm9843:  Predicted gene 9843 
Gnb2l1:  Receptor of activated protein C kinase 1 
Grn:   Granulins 
Gsk3b:  Glycogen synthase kinase-3 beta 
H1f0:   Histone H1.0 
H1fx:   H1 histone family, member X 




H3f3a:  Histone H3.3 
Hba-a1:  Hemoglobin subunit alpha 
Hbb-bs:  Hemoglobin 
Hectd3:  E3 ubiquitin-protein ligase HECTD3 
Hipk2:  Homeodomain-interacting protein kinase 2 
Hira:   Protein HIRA 
Hist1h1a:  Histone H1.1 
Hist1h1b:  Histone H1.5 
Hist1h1c:  Histone H1.2 
Hist1h1d:  Histone H1.3 
Hist1h1e:  Histone H1.4 
Hist1h4j:  Histone cluster 1, H4j 
Hist2h2ab:  Histone H2A type 2-B 
Hist2h3c2:  Histone H3.2 
Hmga2:  High mobility group protein HMGI-C 
Hmgb1:  High mobility group protein B1 
Hmgb2:  High mobility group protein B2  
Hmgn1:  Non-histone chromosomal protein HMG-14 
Hmox:  Heme oxygenase 
Hnrnpa1:  Heterogeneous nuclear ribonucleoprotein A1 
Hnrnpa2b1:  Heterogeneous nuclear ribonucleoproteins A2/B1 
Hnrnph1:  Heterogeneous nuclear ribonucleoprotein H 
Hnrnph2:  Heterogeneous nuclear ribonucleoprotein H2 
Hnrnpk:  Heterogeneous nuclear ribonucleoprotein K 
Hp:   Haptoglobin 
Hrnr:   Hornerin 




Hsp90aa1:  Heat shock protein HSP 90-alpha 
Hsp90ab1:  Heat shock protein HSP 90-beta 
Hsp90b1:  Endoplasmin 
Hspa1b:  Heat shock 70 kDa protein 1B 
Hspa5:  78 kDa glucose-regulated protein 
Hspb7:  Heat shock protein family, member 7 
Id2:   DNA-binding protein inhibitor ID-2 
Ighv1-73:  Immunoglobulin heavy variable 1-73 
Iglc2:   Ig lambda-2 chain C region; Immunoglobulin lambda constant 2 
IL:   Interleukin 
Irf3:   Interferon regulatory factor 3 
Itga:   Integrin alpha 
Itgav:   Integrin alpha-V 
Itgb:   Integrin beta 
Ivl:   Involucrin 
Jph:   Junctophilin 
Jup:   Junction plakoglobin 
Kcmf1:  E3 ubiquitin-protein ligase KCMF1 
Kcnj6:  G protein-activated inward rectifier potassium channel 2 
Kcnk7:  Potassium channel subfamily K member 7 
Kcns3:  Potassium voltage-gated channel subfamily S member 3 
Kdm1a:  Lysine-specific histone demethylase 1A 
Kiaa0922:  Transmembrane protein 131-like  
Klk5:   Kallikrein related-peptidase 5 
Klrg2:   Killer cell lectin-like receptor subfamily G 
Krt:   Keratin 




Lamb:  Laminin subunit beta 
Lamc:  Laminin subunit gamma 
Larp1b:  La ribonucleoprotein domain family, member 1B  
Lbh:   Protein LBH 
Ldb3:   LIM domain-binding protein 3 
Lemd3:  Inner nuclear membrane protein Man1 
Lepre1:  Prolyl 3-hydroxylase 1 
Leprel2:  Prolyl 3-hydroxylase 3 
LGR:   Leucine-rich repeat containing G protein-coupled receptor 
Lias:   Lipoyl synthase 
Limk:   LIM domain kinase  
Lipe:   Hormone-sensitive lipase 
Lmnb1:  Lamin B1 
Lor:   Loricrin 
Loxl1:  Lysyl oxidase homolog 1 
Lpar6:  Lysophosphatidic acid receptor 6 
Lrg1:   Leucine-rich alpha-2-glycoprotein 1 
LRIG1:  Leucine-rich repeats and immunoglobulin-like domains 1 
Lrrc17:  Leucine-rich repeat-containing protein 17 
Ltf:   Lactotransferrin 
Man1a2:  Mannosyl-oligosaccharide 1,2-alpha-mannosidase IB 
Map1b:  Microtubule-associated protein 1B 
Map1lc3a:  Microtubule-associated proteins 1A/1B light chain 3A 
Map2:  Microtubule-associated protein 2 
Map3k11:  Mitogen-activated protein kinase kinase kinase 11 
Mapk:  Mitogen-activated protein kinase 




Mapre3:  Microtubule-associated protein RP/EB family member 3 
Mapt:   Microtubule-associated protein tau 
Mbp:   Myelin basic protein 
mCG_125090:  La ribonucleoprotein domain family, member 1B 
mCG_130165:  RIKEN cDNA 2010005H15 gene 
mCG_130165:  RIKEN cDNA 2010005H15 gene 
Mepe:  Matrix extracellular phosphoglycoprotein with ASARM motif 
Mettl14:  N6-adenosine-methyltransferase non-catalytic subunit 
Mfap:   Microfibrillar-associated protein 
Mllt4:   Afadin 
MMP:   Matrix metalloprotease  
Mmrn:  Multimerin 
Mob4:  MOB-like protein phocein 
Mre11a:  Double-strand break repair protein MRE11 
Mrps:   Mitochondrial ribosomal protein S 
Mst4:   Serine/threonine-protein kinase 26 
Mthfd1:  C-1-tetrahydrofolate synthase, cytoplasmic 
Mtm1:  Myotubularin 
Mybpc2:  Myosin-binding protein C 
Mybpc3:  Myosin-binding protein C 
Mybph:  Myosin-binding protein H 
Myh11:  Myosin-11 
Myl1:   Myosin light chain 1/3 
Myl12b:  Myosin regulatory light chain 12B 
Myl7:   Myosin, light polypeptide 7 
Mylk:   Myosin light chain kinase 




Myom:  Myomesin 
Myot:   Myotilin 
Myoz:  Myozenin 
Mypn:  Myopalladin 
Nckap1l:  Nck-associated protein 1-like 
Nde1:  Nuclear distribution protein nudE homolog 1 
Ndel1:  Nuclear distribution protein nudE-like 1 
Neb:   Nebulin 
Nefl:   Neurofilament light polypeptide 
Nenf:   Neudesin 
Nes:   Nestin 
Nhp2:  H/ACA ribonucleoprotein complex subunit 2  
Nid1:  Nidogen-1 
Nip7:   60S ribosome subunit biogenesis protein NIP7 homolog 
Nlgn:   Neuroligin 
Nnmt:  Nicotinamide N-methyltransferase 
Nono:  Non-POU domain-containing octamer-binding protein 
Nop:   Nucleolar protein 
Npm1:  Nucleophosmin 
Nrap:   Nebulin-related-anchoring protein 
Nrp1:   Neuropilin-1 
Nrxn:   Neurexin 
Nucb1:  Nucleobindin-1Fga: 
Nuf2:   Kinetochore protein Nuf2 
Obscn:  Obscurin 
Ociad2:  OCIA domain containing 2 




Orm:   Alpha-1-acid glycoprotein 
Ost4:   Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 4 
Ostc:   Oligosaccharyltransferase complex subunit  
P4hb:   Protein disulfide-isomerase 
Padi2:  Protein-arginine deiminase type-2 
Pafah1b1:  Platelet-activating factor acetylhydrolase IB subunit alpha 
Pcbp1:  Poly(rC)-binding protein 1 
Pcnx:   Pecanex-like protein 1 
Pcsk9:  Proprotein convertase subtilisin/kexin type 9 
Pcx:   Pyruvate carboxylase, mitochondrial 
Pde4dip:  Myomegalin 
Pdia4:  Protein disulfide-isomerase A4 
Pdia6:  Protein disulfide-isomerase A6 
Peo1:   Twinkle protein, mitochondrial 
Pfdn:   Prefoldin subunit 
Pgm2:  Phosphoglucomutase-1 
Pgm3:  Phosphoacetylglucosamine mutase 
Pgm5:  Phosphoglucomutase-like protein 5  
Phc3:   Polyhomeotic-like protein 3 
Phk:   Phosphorylase b kinase regulatory subunit 
Phkg1: Phosphorylase b kinase gamma catalytic chain 
Picalm:  Phosphatidylinositol-binding clathrin assembly protein 
Piga:   N-acetylglucosaminyl-phosphatidylinositol biosynthetic protein 
Pigm:   GPI mannosyltransferase 1 
Pigr:   Polymeric immunoglobulin receptor 
Pip4k2a:  Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha 




Pip4k2c:  Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma 
Pkp:   Plakophilin 
Plk1:   Serine/threonine-protein kinase PLK1 
Pnpla2:  Patatin-like phospholipase domain-containing protein 2 
Polg:   DNA polymerase subunit gamma-1 
Polg2:  DNA polymerase subunit gamma-2 
Polr1a:  DNA-directed RNA polymerase I subunit RPA1 
Polr1c:  DNA-directed RNA polymerases I and III subunit RPAC1 
Polr1e:  DNA-directed RNA polymerase I subunit RPA49 
Polr2l:  DNA-directed RNA polymerases I, II, and III subunit RPABC5 
Polrmt:  DNA-directed RNA polymerase, mitochondrial 
Pou4f2:  POU domain, class 4, transcription factor 2 
Ppard:  Peroxisome proliferator-activated receptor delta 
Ppp2r1a:  Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A  
Ppp2r5e:  Serine/threonine-protein phosphatase 2A 
Ppp5c:  Serine/threonine-protein phosphatase 5 
Prkac:  cAMP-dependent protein kinase catalytic subunit  
Prkce:  Protein kinase C epsilon type 
Prkg:   cGMP-dependent protein kinase 
Prpf38a:  Pre-mRNA-splicing factor 38A 
Prph:   Peripherin 
Psmg1:  Proteasome assembly chaperone 1 
PTI:   Bos taurus spleen trypsin inhibitor 
Ptpra:  Receptor-type tyrosine-protein phosphatase alpha 
Ptrf:   Caveolae-associated protein 1  
Pygb:   Glycogen phosphorylase 




Rad50:  DNA repair protein RAD50; Component of the MRN complex 
Rasal2:  RAS protein activator like 2 
Rbfox3:  RNA binding protein fox-1 homolog 3 
Rbm14:  RNA-binding protein 14; 
Retn:   Resistin 
Rfk:   Riboflavin kinase  
Rhoa:  Transforming protein RhoA 
Ripply3:  Protein ripply3 
Rnf150:  Ring finger protein 150 
Rpl:   Ribosomal protein L 
Rplp:   Ribosomal protein P 
Rpn:   Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit  
Rps:   Ribosomal protein S 
Rptn:   Repetin 
Ruvbl1:  RuvB-like 1 
Rwdd2b:  RWD domain containing 2B 
Rwdd2b:  RWD domain containing 2B 
Rxra:   Retinoic acid receptor RXR-alpha 
Ryr:   Ryanodine receptor 
Sbspon:  Somatomedin-B and thrombospondin type-1 domain-containing protein 
Scgn:   Secretagogin 
Sdc4:   Syndecan-4 
Sec61a1:  Protein transport protein Sec61 subunit alpha isoform 1 
Sec61g:  Protein transport protein Sec61 subunit gamma 
Serpina3m:  Serine (or cysteine) peptidase inhibitor, clade A, member 3M 
SERPINA5:  Plasma serine protease inhibitor 




Serpinb3b:  Serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 3B 
Serpinb3c:  Serine (or cysteine) peptidase inhibitor, clade B, member 3C 
Serpinh1:  Serpin H1 
Sestd1:  SEC14 domain and spectrin repeat-containing protein 1 
Sfpq:   Splicing factor, proline- and glutamine-rich 
Sgol1:  Shugoshin 1 
Sgsm2:  Small G protein signaling modulator 2 
Sh3gl2:  Endophilin-A1 
Sh3gl3:  Endophilin-A3 
Sirt1:   NAD-dependent protein deacetylase sirtuin-1  
Slc1a2:  Excitatory amino acid transporter 2  
Slmap:  Sarcolemmal membrane-associated protein 
Smpx:  Small muscular protein 
Smyd1:  Histone-lysine N-methyltransferase Smyd1 
Sncg:   Gamma-synuclein  
Snd1:   Staphylococcal nuclease domain-containing protein 1 
Snrnp70:  U1 small nuclear ribonucleoprotein 70 kDa  
Snrp:   U1 small nuclear ribonucleoprotein  
Snrpa:  U1 small nuclear ribonucleoprotein A 
Snrpd:  Small nuclear ribonucleoprotein Sm D 
Snrpd:  Small nuclear ribonucleoprotein-associated protein B 
Snrpe:  Small nuclear ribonucleoprotein E 
Snrpf:  Small nuclear ribonucleoprotein F 
Sorbs2:  Sorbin and SH3 domain-containing protein 2 
SPINK1:  Serine protease inhibitor Kazal-type 1 
Sprr3:  Small proline-rich protein 3 




Sqle:   Squalene monooxygenase 
Src:   Neuronal proto-oncogene tyrosine-protein kinase Src 
Srl:   Sarcalumenin 
Srsf:   Serine/arginine-rich splicing factor   
Ssh:   Protein phosphatase Slingshot homolog 
Ssr4:   Translocon-associated protein subunit delta 
Sssca1:  Sjogren’s syndrome/scleroderma autoantigen 1 homolog 
St8sia3:  Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R-alpha 2,8-sialyltransferase 
Stac3:  SH3 and cysteine-rich domain-containing protein 3 
Staf2l1:  Stefin-2 
Staf3:   Stefin-3 
Stfa1:   Stefin-1 
Stip1:   Stress-induced-phosphoprotein 1 
Stk:   Serine/threonine-protein kinase  
Strip:   Striatin-interacting protein 
Stt3a:  Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 
STT3A 
Stt3b:  Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 
STT3B 
Suds3:  Sin3 histone deacetylase corepressor complex component SDS3 
Sun2:   SUN domain-containing protein 2 
Syk:   Tyrosine-protein kinase SYK 
Sync:   Syncoilin 
SYNM:  Synemin 
Sypl2:  Synaptophysin-like protein 2 
Taf1:   TATA box-binding protein-associated factor RNA polymerase I subunit 




Tatdn1:  Putative deoxyribonuclease TATDN1  
Tbl1x:  F-box-like/WD repeat-containing protein TBL1X 
Tbp:   TATA-box-binding protein 
Tcap:   Telethonin 
TELO2:  Telomere maintenance 2 
Tfam:   Transcription factor A, mitochondrial 
Tgm1:  Protein-glutamine gamma-glutamyltransferase K 
Tigd:   Tigger transposable element derived 3  
Timp:   Metalloproteinase inhibitor  
Tln1:   Talin-1 
Tnnc2:  Troponin C, skeletal muscle 
Tnni1:  Troponin I, slow skeletal muscle 
Tnni2:  Troponin I, fast skeletal muscle 
Tnni3:  Troponin I 
Tnni3:  Troponin I, cardiac muscle 
Tnnt2:  Troponin T, cardiac muscle 
Tnnt3:  Troponin T, fast skeletal muscle 
Tnr:   Tenascin-R 
Topbp1:  DNA topoisomerase 2-binding protein 1 
Tpm1:  Tropomyosin alpha-1 chain 
Tpm2:  Tropomyosin beta chain 
Tpm4:  Tropomyosin alpha-4 chain 
Tpt1:   Translationally controlled tumor protein 
Trdn:   Triadin 
Trim:   Tripartite motif-containing  
Trim54:  Tripartite motif-containing protein 54 




Trp53:  Cellular tumor antigen p53 
Trp53inp1:  Tumor protein p53-inducible nuclear protein 1 
Trp63:  Tumor protein 63 
Trpc3:  Short transient receptor potential channel 3 
Trtr:   Transthyretin 
Tsc22d3:  TSC22 domain family protein 3 
Tspyl5:  Testis-specific Y-encoded-like protein 5 
Ttf1:   Transcription termination factor 1 
Ttll3:   Tubulin monoglycylase TTLL3 
Ttn:   Titin 
Ttr:   Transthyretin 
Tubb3:  Tubulin beta-3 chain 
Tusc3:  Tumor suppressor candidate 3 
U2af2:  Splicing factor U2AF 65 kDa subunit 
Uba:   SUMO-activating enzyme subunit  
Ube2:  Ubiquitin-conjugating enzyme E2 B 
Ube2a:  Ubiquitin-conjugating enzyme E2 A 
Ube2o:  (E3-independent) E2 ubiquitin-conjugating enzyme UBE2O 
Ube2u:  Ubiquitin-conjugating enzyme E2U 
Ube2z:  Ubiquitin-conjugating enzyme E2 Z 
Ubn:   Ubinuclein 
Ubr:   E3 ubiquitin-protein ligase UBR 
Ugp2:  UTP--glucose-1-phosphate uridylyltransferase 
Ugt1a6b:  UDP-glucuronosyltransferase 
Ugt1a7c:  UDP-glucuronosyltransferase 1-7C 
Ugt2b1:  UDP-glucuronosyltransferase 




Vcan:   Versican core protein 
Vcl:   Vinculin 
Vim:   Vimentin 
Vps:   Vacuolar protein sorting-associated protein 
Vta1:   Vacuolar protein sorting-associated protein VTA1 homolog 
Vtn:   Vitronectin 
Wasl:   Neural Wiskott-Aldrich syndrome protein 
Wdr:   WD repeat-containing protein  
Wrb:   Tail-anchored protein insertion receptor WRB 
Wrn:   Werner syndrome ATP-dependent helicase homolog 
Wwtr1:  WW domain-containing transcription regulator protein 1 
Xkr6:   XK-related protein 6  
Zc3h12c:  Probable ribonuclease ZC3H12C 
Zcrb1:  Zinc finger CCHC-type and RNA binding motif 1 
Zfr:   Zinc finger RNA-binding protein 
Zw10:  Centromere/kinetochore protein zw10 homolog 
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